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ABSTRACT 
Objectives: Ovarian Cancer is considered the most lethal gynaecological disease with over 9 
million women dying annually on a global scale. Current standards of care which consists of 
debulking surgery and adjuvant chemotherapy are proving to be inadequate due to 
chemoresistance whilst targeted-therapies available are limited. This prompts research into 
identifying the therapeutic potential of animal venoms in relation to ovarian cancer.  
Materials and Methods: Using a 50% threshold, the ability of crude venom from Parabuthus 
transvaalicus (Transvaalicus thick-tailed scorpion), Heterometrus madraspatensis (Madras 
forest scorpion) and Heterometrus mysorensis to inhibit SK-OV-3 cell metabolism was analysed 
using dose response assays. Furthermore, fractioned venoms Naja nigricollis_r11 (Black-necked 
spitting cobra) and Pandinus cavimanus_r28 (Tanzanian red clawed scorpion) were also 
investigated for their inhibitory effects on the cell line.  
Results: Crude Parabuthus transvaalicus venom at a concentration of 200µg/ml inhibited 
44.55% of SK-OV-3 cell metabolism. Heterometrus madraspatensis and Heterometrus 
mysorensis venom at a concentration of 500µg/ml inhibited 0.78% and 2.35% of cell metabolism 
respectively. Fractioned venom Pandinus cavimanus_r28 at a concentration of 15.63µg/ml 
inhibited 2.54% of cell metabolism whilst Naja nigricollis_r11 venom fraction produced an LD50 
of 37.23µg/ml.   
Conclusion: Parabuthus transvaalicus, Heterometrus madraspatensis, Heterometrus mysorensis 
and Pandinus cavimanus_r28 at the specified concentrations did not reach the inhibition 
threshold of 50% in regards to the SK-OV-3 cell line and were therefore not investigated further. 
The Naja nigricollis_r11 fraction exceeded the 50% threshold thus identifying as a positive hit 
and warrants further analysis.  
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INVESTIGATING THE EFFECTS OF ANIMAL VENOMS IN OVARIAN CANCER 
CHAPTER ONE: LITERATURE REVIEW  
1.1. Introduction  
Research currently shows that non-communicable diseases (NCD’s) are the leading causes of 
death worldwide. According to the World Health Organisation (WHO) Global Health Observatory 
Data, NCD’s amount to around 3ϲ million deaths annually. Diseases in this category include 
cardiovascular disease, chronic lung disease, diabetes and cancer (Kim & Oh, 2013).  
Of these diseases, cancer has been ranked as the leading cause of death and a major obstacle 
with regards to increasing life expectancy on a global scale. Factors including growth in 
populations and individuals living longer contribute to the increase in incidence and mortality of 
cancer as well as growth in established risk factors such as obesity, physical inactivity and 
smoking (Bray, et al., 2018).  
GLOBOCAN and The International Agency for Research on Cancer have shown that in 2018 alone 
there were over 18 million new cases of cancer and over 9 million deaths globally (Ferlay, et al., 
2018). Relating this to previously published data, GLOBOCAN in 2012 estimated that there were 
14.1 million new cases of cancer and 8.2 million deaths on a global scale (Torre, et al., 2015); 
this is an increase of 28.6% and 9.8% respectively. Although relatively more advanced 
treatments are employed in the battle against cancer, these statistics still highlight areas of 
treatment ineffectiveness. 
One cancer of great concern to the female population is ovarian cancer (OC). On an annual scale, 
OC will affect around 239,000 individuals and cause 152,000 deaths worldwide (Reid, et al., 
2017). Alternatively, in the UK alone there are around 7,000 new cases diagnosed and 4,000 
deaths each year making it the sixth most common cancer in association with the female 
populace (Cancer Research UK, 2018). Unfortunately, due to the elusive, non-specific symptoms, 
especially early on, women are diagnosed at a much later stage making the disease harder to 
treat (Ebell, et al., 2016).  
Non-targeted treatments for OC include surgery and chemotherapy. Although such treatments 
have improved over the years, they are becoming increasingly ineffective with more women 
dying due to drug resistance diseases (Bookman, et al., 2009). Furthermore, non-targeted 
treatments tend to have more side effects for patients including hair loss and muscular ache 
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effecting a patient’s quality of life (Hsu, et al., 2017). This ensures a need for more research into 
the area of targeted, novel therapies. Targeted-therapies are of popular choice in research due 
to their specificity in pursuing cancerous-cells increasing treatment effectiveness for certain 
patients. Such therapies include antiangiogenic agents, poly-ADP-ribose polymerase (PARP) 
inhibitors and targeting of the epidermal growth factor receptor (EGFR) (Coward, et al., 2015).  
When considering the side effects and poor outcomes of certain treatments associated with OC, 
the development of alternative treatments is imperative for the survival of individuals with the 
disease. One such area of research that is currently being explored is the development of novel 
treatments utilising animal venoms (Moridikia, et al., 2018). Venoms contain a cocktail of varying 
proteins and peptides which target physiological processes within the body; these include cell 
proliferation, migration, invasion and apoptotic activity which are considered as hallmarks of 
cancer (Chaisakul, et al., 2016). It is therefore possible to isolate proteins and peptides within 
the cocktail to target certain cellular processes which influence the survival of tumorogenesis 
(Tan, et al., 2018).  
In this review, the cellular processes associated with OC, the current therapies available and new 
alternative targets for treatment will be highlighted. Contemporary research and advances 
made through the utility of anticancer properties in venom will also be discussed.  
1.2. Ovarian Cancer: Classification and Mechanisms   
It is not as straightforward to identify OC as a single homogenous disease as it was once 
regarded. Instead, considerations over the years have acknowledged a breakdown of the disease 
identifying and categorising types of OC, establishing a staging classification and asserting a 
grading system thus inaugurating a heterogeneous disease (Wang, et al., 2005). Developments 
such as those stated above have assisted in the deeper understanding of the disease ultimately 
aiding in the optimisation of treatment plans which is paramount for survival (Javadi, et al., 
2016). 
 1.2.1. Staging Classification  
OC can be divided and subdivided into several stages. Staging describes the location of the 
primary-tumour, the size and if the tumour has spread which can ameliorate the prognosis of 
the disease (Forstner, et al., 2016). There are two leading staging classifications currently 
utilised; the number staging system developed by The International Federation of Gynaecology 
and Obstetrics (FIGO) as illustrated in Table 1.1 (Mutch & Prat, 2014), as well as the tumour, 
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node and metastasis (TNM) staging system developed by the American Joint Committee on 
Cancer and the Union for International Cancer Control (Union for International Cancer Control, 
2017). Amendments over the years have ensured their effectiveness. The TNM staging system 
is now on its eighth-edition whilst the FIGO staging classification, originally constructed in 1988, 
was revised in 2013 (Shepherd, 1989). Revisions included the realisation that cancer of the 
ovary, fallopian tube and peritoneum are of similar nature and should be considered mutually; 
furthermore, stage IC was divided into 3 sub-stages for additional specificity (Sartorius, et al., 
2018). Such modifications offer explicit guidance on personalised management of the disease 
(Kandukuri & Rao, 2015).  
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Table 1.1. The now revised 2013 accepted staging of OC as developed by The International Federation of 
Gynaecology and Obstetrics (FIGO). Table adapted from (FIGO, 2015) source.  
STAGE OF OC DESCRIPTION 
Stage I 
 
IA 
 
 
 
IB 
 
 
 
IC 
 
 
x IC1 
x IC2 
 
x IC3 
Tumour isolated to ovaries or fallopian tube(s) and has not spread 
 
Tumour is located in one ovary or fallopian tube; confined to the inside of 
said ovary or fallopian tube. Tumour not detected on the surface of ovary 
or fallopian tube and no malignant cells found in peritoneal washings  
 
Tumour is located in both ovaries or fallopian tubes; tumour not detected 
on the surface of ovaries or fallopian tubes and no malignant cells found 
in peritoneal washings 
 
Tumour located in one or both ovaries or fallopian tubes, with any of the 
following; 
 
x Ruptured capsule during surgery  
x Capsule ruptured before surgery or tumour on ovary or fallopian 
tube surface  
x Malignant cells in peritoneal washings  
Stage II 
 
 
IIA 
 
 
IIB 
Tumour involves one or both ovaries or fallopian tubes and has spread to 
pelvis region  
 
Extension and/or implants on uterus and/or fallopian tubes and/or 
ovaries  
 
Extension to other regions near the pelvis  
Stage III 
 
 
 
IIIA1 
 
x IIIA1(i) 
x IIIA1(ii)  
 
IIIA2 
 
 
IIIB 
 
 
 
IIIC 
Tumour involves one or both ovaries or fallopian tubes, pelvis region 
and/or the retroperitoneal lymph nodes 
 
Positive retroperitoneal lymph nodes only (cytologically or histologically 
proven) 
 
x Metastasis up to 10mm in greatest dimension 
x Metastasis more than 10mm in greatest dimension 
 
Microscopic extrapelvic peritoneal involvement with or without positive 
retroperitoneal lymph nodes 
 
Tumour less than 2cm in the greatest dimension visible outside pelvis and 
retroperitoneal lymph nodes and may or may not contain cancerous-cells  
 
Tumour is more than 2cm in the greatest dimension visible outside pelvis 
and retroperitoneal lymph nodes. May also be on the outside of liver or 
spleen  
Stage IV 
 
IVA 
 
IVB 
Cancer has spread beyond the pelvis and to other organs  
 
Cancer-cells are identified in the fluid around the lungs  
 
Cancer spread and identified inside spleen, liver, lungs and bones   
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1.2.2. Type and Molecular Characteristics  
There are 3 common cell types whereby OC can start from as illustrated in Figure 1.1. Epithelial 
cells, which form the surface layers of the ovaries, account for 90% of all OC (Israelsson, et al., 
2017). Stromal cells, which make up the core of the ovaries, and germ cells, which develop into 
eggs, both contribute to 5% each of OC’s as stated in Table 1.2 (Phyoe-Battaglia, et al., 2018, 
Park, et al., 2015). Epithelial-OC is the most common with 75% of women being diagnosed at 
much later stages in the disease, consequently having a fatal impact on the effectiveness of 
treatment and survival. 
 
Figure 1.1. Diagram illustrating an ovary cell and the components which contribute to the formation of 
OC. This includes the epithelium, the stroma and germ cells. 
 
 
Early 
Corpus 
Luteum 
Corpus 
Luteum 
Epithelium 
Stroma 
Capsule 
Germ 
Cells 
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Table 1.2. The frequency and types of OC associated with the epithelium, germ cells and the stroma 
(Cancer Research UK, 2018).  
 
 
 
Epithelial-OC is now sub-divided into serous (high-grade or low-grade), endometrioid, clear-cell 
and mucinous histotypes (Cheng, et al., 2005, Koshiyama, et al., 2017). Instead of considering 
them as one disease, each histotype is its own distinct disease differing in molecular 
characteristics, ways of metastasising and treatment plan. Further categorisations using various 
molecular and histopathological studies have now distinguished two types of epithelial-OC. Type 
I, accounting for 5-10% of deaths, includes low-grade endometrioid-OC (LGEOC), clear cell-OC, 
mucinous-OC and low-grade serous-OC (LGSOC). Type II on the other hand, accounting for 90% 
of deaths, includes high-grade serous-OC (HGSOC) and high-grade endometrioid-OC (HGEOC) 
(Garziera, et al., 2018).  
Extensive research has identified key mutations associated with molecular characteristics which 
permits the recognition of the aforementioned subtypes and this is clarified in Table 1.3. Somatic 
mutations in the tumour suppressor gene TP53 for example, are a major indication of type II OC. 
The Cancer Genome Atlas, for instance, analysed the DNA sequence of exons from coding genes 
of 31ϲ HGSOC’s and established that ϵϲй of these tumours had a mutation in the TP53 gene 
(The Cancer Genome Atlas Research Network, 2011).  Similarly, Cole et al 2016, using 
immunohistochemistry (IHC) and massively parallel sequencing, identified the TP53 gene was 
mutated in 94% of HGSOC’s (Cole, et al., 2016).  
In addition to this research, Yaginuma and Westphal 1992, using immunoprecipitation and the 
monoclonal antibody PAb421 (raised to wild-type p53), identified that the p53 protein was not 
detectable in the Caov-3 and SK-OV-3 (an established HGSOC) cell lines which express the TP53 
gene.  This suggests that these cell lines are mutated through a loss-of-function (LOF) of the TP53 
gene as there was no production of the p53 protein. As this protein is responsible for regulating 
cell division and preventing uncontrolled proliferation, the LOF to the gene prevents the 
production of the protein and thus control, allowing for the unrestrained proliferation of 
tumour-cells (Yaginuma & Westphal, 1992). 
 Epithelial Cells  Germ Cells Stroma  
Frequency 90% 5% 5% 
Types Serous  
Mucinous 
Endometroid 
Clear cell  
Mature Teratomas  
Immature Teratomas 
Dysgerminomas 
Yolk Sac Tumours  
Choriocarcinomas  
Granulosa cell 
Thecoma 
Fibroma 
Sertoli-Leydig 
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Alternatively, type I OC’s are usually associated with mutations in KRAS, PIK3CA, PTEN or BRAF 
(Kurman & Shih, 2010). Singer et al 2003, analysed the KRAS gene and its downstream mediator 
BRAF, at codon 599 for BRAF and codons 12 and 13 for KRAS in LGSOC’s and low-grade serous 
borderline tumours (LGSBT); results showed that mutations in the selected codons of either 
BRAF or KRAS transpired in ϲϴй of LGSOC’s and ϲ1й of LGSBT. On the other hand, of the ϳ2 
HGSOC’s analysed, no mutations were found in BRAF or KRAS highlighting their mutation 
specificity for type I LGSOC (Singer, et al., 2003). Similarly, McConechy et al 2014, using select 
exon capture sequencing on a panel of genes, identified that PTEN mutations were found in 67% 
of LGEOC (McConechy, et al., 2014), whilst Kolasa et al 2006, using single-strand conformation 
polymorphism and sequencing, found that PTEN and KRAS mutations occurred in 80% of the 
LGEOC (Kolasa, et al., 2006). This emphasises the association of mutations to specific cancer 
subtypes aiding with identification.  
Table 1.3. The types of mutations which can be identified in particular types of OC; භ indicates that the 
mutation is present and ԉ indicates that the mutation is not present.  
 
 
 
 
 
Similarly, EGFR has known to be overexpressed in epithelial-OC and occurs in all histological 
subtypes providing an association to poor prognosis and decreased therapeutic responsiveness 
(Li, et al., 2016). Wang et al 2016, using immunohistological staining and statistical analysis of 
242 patients with epithelial-OC, found that there was a significant correlation between the level 
of EGFR (in tumour-cells and tumour stroma) with clinical stage (p values=0.005 and 0.008 
respectively) and distant metastasis (p value<0.001 for both) (Wang, et al., 2016).  
In regards to the various types of OC and the differing stages and grades, treatment plans have 
become more tailored to the individual’s cancer. However, as previously touched upon, cancer 
treatments are still proving to be inadequate regardless of such breakthroughs in disease 
specificities and this is down to a lack of advancements within the sector of targeted-therapies 
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for OC. Novel treatment strategies are essential in order to improve such negative statistics 
related to OC. Therefore, identifying and capitalising upon the various molecular-targets 
associated with cancer survival is crucial. This will assist in the development of better treatment 
strategies for OC patients and thus improve the outcome.   
1.3. Potential Molecular-Targets in Ovarian Cancer  
Molecular-targets are specific molecules which are involved in the growth and progression of 
cancer; they are therefore key elements which need to be addressed in the investigation into 
improving the survival of OC through precision medicine (Ke & Shen, 2017). Approaching this 
may involve identifying specific proteins involved in cancer progression which are distinctively 
present or overexpressed in cancer-cells. LOF or mutation of other particular proteins which play 
a crucial role in cancer development may also be identified (Abdelmoez, et al., 2017). If a 
compelling molecular-target is established, research into developing therapies which impair the 
cancerous function of the specific molecules can be employed, ultimately selecting tumour-cells, 
inducing apoptosis and impeding progression (Itamochi, 2010).  
One molecular-target of interest in OC is EGFR. This receptor is a part of the ErbB family of 
structurally related proteins, Her1 (EGFR), Her2 (ErbB2), Her3 (ErbB3) and Her4 (ErbB4) which 
are part of a larger family of receptor tyrosine kinases (RTK’s). They are a collection of high-
affinity cell surface receptors with a preciseness for growth factors, cytokines and hormones 
(McCullough & Trim, 2015). Each member of the family encompasses an intracellular 
juxtamembrane and large extracellular region, a tyrosine kinase and transmembrane domain 
and a carboxyterminal tail illustrated in Figure 1.2 (Ferguson, 2008). The regulation of the ErbB 
family is dependent on various ligands (known as growth factors) which can bind to the 
receptors distributed on the cell surface membrane as clarified in Table 1.4 (Yarden & 
Sliwkowski, 2001).  
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Figure 1.2. Diagram representing the structure of a typical RTK, in particular EGFR. The large extracellular 
region consists of 4 domains. Domains I and III are known as leucine rich domains which display a β-helical 
fold whilst domains II and IV contain cysteine rich motifs thus known as cysteine rich domains. Domain III 
is responsible for ligand binding (Ferguson, 2008). The transmembrane domain is hydrophobic and spans 
across the cell membrane. The juxtamembrane domain is located just inside the cell membrane followed 
by the protein kinase domain which plays an important role in the regulation of cell proliferation and 
differentiation (Voldborg, et al., 1997). Finally, the carboxyterminal tail plays a crucial role in the 
regulation of enzyme activity of the tyrosine kinase domain (Gajiwala, 2013).  
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Table 1.4. The ligand interactions in the EGF family of receptors; භ indicates interaction and ԉ indicates 
there is no interaction (Yarden & Sliwkowski, 2001). High affinity ligands bind to the receptor 10- to 100- 
fold more than low affinity ligands (Freed, et al., 2017); as they all activate EGFR these ligands are known 
as EGFR agonists. Neuregulins are ligands which bind HER3 and HER4.   
 
 
 
 
 
 
The incessant mutation and overexpression of EGFR is evident in various cancers including lung, 
breast, glioblastoma and OC (Sigismund, et al., 2017). The receptor is associated with signalling 
pathways, including Ras-Raf-MAPK pathway (Molina & Adjei, 2006), the Jak/STAT pathway 
(O'Shea, et al., 2015)  and PI3K/AKT/mTOR pathway (Porta, et al., 2014) all of which are involved 
in cell division, survival and growth of cancer-cells as illustrated in Figure 1.3.  
 
 
 
 
 
 
 
 
  Receptor Type 
 Ligand EGFR HER2 HER3 HER4 
High 
Affinity 
Ligands 
EGF භ ԉ ԉ ԉ 
TGF-α භ ԉ ԉ ԉ 
BTC භ ԉ ԉ භ 
HB-EGF භ ԉ ԉ භ 
Low 
Affinity 
Ligands 
EREG භ ԉ ԉ භ 
EPGN භ ԉ ԉ ԉ 
AREG භ ԉ ԉ ԉ 
Neuregulins 
NRG1 ԉ ԉ භ භ 
NRG2 ԉ ԉ භ භ 
NRG3 ԉ ԉ ԉ භ 
NRG4 ԉ ԉ ԉ භ 
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Figure 1.3. Simple diagram illustrating the interaction between EGFR and subsequent initiation of 
signalling pathways. Ligand binding to EGFR contributes to the exposure of the dimer interface of the 
receptor and activation of the cytoplasmic domains. During this interaction, phosphorylation of tyrosine 
residues from adenosine triphosphate (ATP) occurs with the aid of a kinase enzyme. As a result, either 
homo-dimerisation or hetero-dimerisation ensues which ultimately inaugurates downstream signalling 
pathways associated with EGFR activation (Zhu, et al., 2019). Jak/STAT, PI3K/AKT/mTOR and MAPK 
signalling pathways are initiated when EGFR is activated. This diagram also illustrates the MAPK signalling 
pathway in more depth through exemplifying the interactions involved in the pathway, which ultimately 
result in the physiological processes stated. When EGF binds to EGFR, Y1068 and Y1086 tyrosine residues 
bind directly to Growth Factor Receptor Binding Protein 2 (GRB2). Once bound, Src Homology and 
Collagen (SHC) is phosphorylated allowing itself to become a binding site for GRB2. Following this, the two 
SH3 domains on GRB2 bind to Sons of Sevenless 1 (SOS1) through the proline rich carboxyltail. SOS1 then 
activates RAS by instigating the exchange of guanosine diphosphate (GDP) to guanosine triphosphate 
(GTP). Through doing this, RAS can then interact with RAF1 which consequently activates MAPK ERK 
Kinase (MEK) 1/2 through the phosphorylation of serine residues at 217 and 221. MEK 1/2 can then 
activate Extracellular Signal-Regulated Kinase (ERK) 1/2 through phosphorylating the thr-glu-tyr motif in 
ERK 1/2 which can then phosphorylate various substrates to induce a biological response such as 
angiogenesis (Wee & Wang, 2017). 
It is important to establish that EGFR is not solely identifiable in cancerous-cells but are 
expressed on normal cells, predominantly of epithelial origin. Expression levels can range from 
40,000 to 100,000 receptors per cell (Harding & Burtness, 2005). To put overexpression of the 
receptor into perspective, some cancer-cells have been established to express 2x106 receptors 
per cell, this is at least twenty times greater than normal cells (Milenic, et al., 2008). The 
amplified expression of the receptor on the cell allows for heightened activation thus increasing 
the stimulation of cell signalling pathways associated with certain hallmarks of cancer.  
Nielsen et al 2004, using IHC, demonstrated that EGFR was overexpressed in 62% of 783 
epithelial-OC patients (Nielsen, et al., 2004). In addition to this, Milenic et al 2008, compared 
the overexpression of EGFR in various cell lines, including SK-OV-3, to the A431 cell line (EGFR 
expression level of 2x106 receptors per cell). The percentage of cells positive for EGFR and the 
mean fluorescence intensity (MFI) of EGFR expression was measured using flow-cytometric 
techniques. Results indicated that 99.7% of SK-OV-3 cells were positive for EGFR, whereas 95.4% 
of A431 cells were positive. Additionally, the level of EGFR expression for A431 cells had an MFI 
result of 1480.5 in comparison to 452.9 for SK-OV-3 cells. Although this seems like a dramatic 
decrease, SK-OV-3 cells had the second highest level of expression (Milenic, et al., 2008). This 
demonstrates that there are more cells that contain the receptor in SK-OV-3 compared to A431, 
whereas there are more receptors per cell in A431 in comparison to SK-OV-3. Ultimately, these 
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results highlight that SK-OV-3 expresses an excessive level of EGFR demonstrating a compelling 
molecular-target when considering precision medicine.  
In addition to EGFR, vascular endothelial growth factor receptor (VEGFR) has shown to be 
overexpressed in SK-OV-3 cells also (as mentioned in Section 1.4.2) (Spannuth, et al., 2009). This 
receptor regulates the process of angiogenesis (formation of new blood vessels), a critical 
process in the growth of cancer as well as invasion and metastasis (Benedito, et al., 2012). For 
its dominant role in the progression of cancer whilst proving to aid in the poor prognosis of OC, 
this receptor is another molecular-mark that therapies can target to impair tumour-cells.  
Targets which cause tumorogenesis are clearly an excellent focus, however, identifying 
molecular mechanisms familiar in cancerous and normal cells can be exploited in the 
degradation of tumours. PARP is a protein found in most cells with the role of repairing single-
stranded DNA breaks through the utilisation of the base excision repair pathways (Morales, et 
al., 2016). Through inhibiting PARP’s, the mechanism of repairing single-stranded DNA breaks is 
impaired which eventually leads to cell death (Lin & Kraus, 2017). Cells also use the homologous 
recombination repair (HRR) mechanism, which involves the BRCA1 and 2 genes, to repair 
double-stranded DNA breaks; this means cells with a working HRR mechanism and healthy BRCA 
genes are less susceptible to the effects of PARP inhibitors (Roy, et al., 2012). However, cells 
with faulty BRCA genes, as witnessed in HGSOC (Neff, et al., 2017), impair the ability of double-
stranded DNA breaks being corrected and are therefore more vulnerable to the effects of PARP 
inhibitors, making cell death more imminent (Chandna, 2019).  
Considering the examples outlined here, molecular-markers must have a strong ascendancy 
with the hallmarks of cancer (Hanahan & Weinberg, 2011) and therefore able tumorogenesis in 
some form. Such mutations are usually specific to not only the form of cancer but the histotypes 
associated with those forms. Due to the specificity, this makes the molecular-targets distinct 
and thus lays the foundations for research into precision medicines which has resulted in the 
successful development of targeted-treatments (Section 1.4.2).  Unfortunately, OC remains as 
the most lethal gynaecologic malignancy (Du, et al., 2015), however, continuing to establish 
molecular-marks and exploring unprecedented routes of treatments will surely improve the 
outcomes for OC patients in the near future.  
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1.4. Contemporary Treatments in Ovarian Cancer  
Symptoms associated with OC include pain and pressure in the pelvis, back pain and change in 
bowel habits (National Health Service , 2017). Ambiguous symptoms such as these are 
commonly misdiagnosed for irritable bowel syndrome, menstruation and dyspepsia. By 
extension only 25% of women will be diagnosed at stages I and II whilst 75% are diagnosed at 
stages III and IV, by which point the cancer has spread (Ebell, et al., 2016). This explains why 
over 239,000 women are diagnosed worldwide annually with OC (Reid, et al., 2017) and 
accounts for approximately 5% of cancer related deaths among women; greater than any other 
gynaecological disease (American Cancer Society , 2019). With this in mind, the progression and 
development of therapies utilised in the treatment of OC are imperative for survival. 
1.4.1. Non-Targeted Therapies  
Non-targeted therapies do not specifically target cancer-cells and their genomic modifications, 
instead such therapies work by ostracising cells in the body that grow and divide quickly 
(Athauda, et al., 2019). Unfortunately, with lack of specificity, healthy cells may also be attacked 
consequently increasing the number and severity of side effects (Kayl & Meyers, 2006). This is 
not said to discredit the impact non-targeted therapies have had over the decades, nonetheless, 
progression in medicine is required to overcome barriers such as resistance.  
Existing non-targeted therapies commonly used in the process of treating OC include surgery 
and chemotherapy (Eisenkop & Spirtos, 2001). The current standard of care includes initial 
debulking surgery and adjuvant platinum/taxane based chemotherapy (Lheureux, et al., 2015). 
1.4.1.a. Surgery  
Surgery is an important first-line intervention in the early treatment of OC (Meigs, 1934). It is 
initially utilised to remove and stage the cancer; this is achieved through an omentectomy, 
sampling of the pelvic region and peritoneal or abdominal washings. Research suggests there is 
a direct association between cytoreductive surgery and prognosis (McGuire III & Markman, 
2003, Iura, et al., 2018). Surgery is commonly used as a singular therapy in stage I OC whilst all 
efforts are made to sustain fertility (Schorge, et al., 2018). Adjuvant chemotherapy is also not 
necessary for this stage, instead an active surveillance programme is operated involving regular 
clinical reviews and examinations including abdomen and pelvic sonography; this ensures 
optimal survival and maintains a reoccurrence rate of 15-25% (Ray-Coquard, et al., 2018). 
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Surgery which salvages reproductive capability is highly unlikely with regards to advanced stage 
OC as both ovaries and/or fallopian tubes are involved. Instead a total-abdominal-hysterectomy 
and bilateral-salpingo-oophoectomy are performed; this involves the removal of both ovaries 
and fallopian tubes as well as the womb and cervix (Katz, et al., 2019).  
As alluded to, surgical debulking followed by platinum-based chemotherapy is the primary 
standard of care for advanced OC. However, some researchers have investigated the potential 
benefits of neoadjuvant chemotherapy as well as interval debulking surgery (IDS) (Schorge, et 
al., 2010). Kehoe et al 2015, in a phase 3 trial undertaken in 87 hospitals in the UK and New 
Zealand, randomly assigned stage III and IV OC patients to either primary surgery followed by 6 
cycles of adjuvant chemotherapy or 3 cycles of chemotherapy, IDS, followed by 3 more 
chemotherapy cycles. Results showed that the median overall survival (MOS) was 24.1 months 
compared to 22.6 months in favour of the primary chemotherapy with IDS. Furthermore, 24% 
(primary surgery) compared to 14% (primary chemotherapy with IDS) of women died within 28 
days of surgery (p-value=0.0007) (Kehoe, et al., 2015). These results were emphasised further in 
similar research carried out by Vergote et al 2010, establishing the benefits of neoadjuvant 
chemotherapy and IDS (Vergote, et al., 2010). Subsequent to these studies, Meyer et al 2016, 
indicated that there was an increase in the use of neoadjuvant chemotherapy from 16%, starting 
in 2003 to 2010, to 24%, during 2011-2012 for stage III OC, whilst stage IV OC saw an increase 
from 41% to 62% respectively (Meyer, et al., 2016). Such research highlights why progression 
and development in medicine is obligatory.  
1.4.1.b. Chemotherapy  
Chemotherapy is a common treatment used across a range of cancers and has made huge 
progressions with goals of curing, controlling or palliating the disease (Chabner & Roberts Jr, 
2005). Using cytotoxic drugs which circulate in the bloodstream, rapidly dividing cells such as 
cancer-cells are attacked through the prevention of DNA replication (Frezza, et al., 2017). It has 
been suggested that OC was one of the first tumours to be treated by means of chemotherapy 
with the use of single alkylating agents (AA). This was considered as the optimal treatment plan 
for OC up until the mid-1ϵϳ0’s with median survival among recipients ranging from 1ϳ to 20 
months (BMJ, 1991). However, as documented in Table 1.5, there have been multiple 
advancements in the field of chemotherapy over the decades ultimately leading to the optimal 
treatment plan of platinum/taxane based chemotherapy used today (Katsumata, et al., 2013).  
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A common theme however, which can be attributed to the multiple progressions in 
chemotherapy regimens, is in fact chemoresistance; this is when the cancer-cells become 
unaffected by the cytotoxic drugs used in chemotherapy and thus continue to thrive. 
Chemoresistance is a huge challenge in the therapeutics community and is a huge impediment 
to the long-term success of treatment (Asare-Werehene, et al., 2019). Unfortunately, due to 
chemoresistance, as many as 70-80% of OC patients will succumb to the disease as there are no 
alternative treatment options (Granados, et al., 2015). A few brief examples of this are 
demonstrated in Table 1.5. Young et al 1978, initially found that combining AA in the treatment 
of OC increased MOS by 12 months in advanced stage OC patients compared to monotherapy 
(p-value=0.02) (Young, et al., 1978). However, this therapy regimen was quickly reviewed when 
chemoresistance to AA increased; this instigated the eventual research by Neijt et al 1984, into 
the combination of cisplatin with cyclophosphamide, which significantly improved the MOS (p-
value=0.002) (Neijt, et al., 1984). Once more, cyclophosphamide, as an AA, proved to become 
more ineffective, this prompted further research into alternative therapies. This resulted in 
Piccart et al 2000, and Neijt et al 2000, publishing research on the significant benefits of 
combining paclitaxel with either cisplatin or carboplatin with an increase in MOS of 9.8 months 
and an average of 81.4 months respectively (Piccart, et al., 2000, Neijt, et al., 2000).  
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Table 1.5. Primary research published from 1978 to 2013 representing key advancements made in the 
development of therapies for OC ultimately progressing to the optimal treatment regimen available 
today.  
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Tumours can be intrinsically resistant preceding to chemotherapy (attributed to the existence 
of cancer stem cells) (Zheng, 2017) or the resistance can be acquired throughout treatment 
(attributed to genetic and epigenetic dysregulation of onco- and tumour suppressor genes) (Liu, 
et al., 2012). Drug resistance is extremely complex due to its multi-factorial phenomenon; 
factors contributing to resistance include accelerated drug-efflux, alterations in drug target, DNA 
methylation and evasion of apoptosis (Pan, et al., 2016). Another common cause of 
chemoresistance is drug-inactivation, commonly noted in OC patients in relation to platinum-
based therapies. This mechanism involves glutathione (a powerful antioxidant found in all living 
organisms). Glutathione forms conjugates with platinum-based drugs, such as cisplatin or 
carboplatin, and inactivates the cytotoxic effects of the drug through inhibiting oxidative stress 
which would have the potential to damage RNA and DNA of the tumour-cells which is evident in 
SK-OV-3 (Mistry, et al., 1991). Furthermore, when the platinum-based drugs covalently link to 
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glutathione, a substrate for ATP-binding-cassette-transporter proteins is produced resulting in 
drug-efflux, another form or chemoresistance (Wilson, et al., 2006).  
Treatment failure is having a huge impact on the success and survival of OC. Reviewing the 
previous topics discussed regarding non-targeted therapy, it is clear that a lack of specificity with 
the use of a ‘one-size-fits-all’ therapeutic approach, chemoresistance is increasing. Using non-
targeted therapies is resulting in transient responses diminishing survival of the disease, 
especially if progression in drug development is not made. This is why there is an enormous 
requirement for research to delve into targeted-therapies which will improve the effectiveness 
of treatment, increase the number of women who survive the disease and overcome 
chemoresistance. 
1.4.2. Targeted Therapies  
Alternative to non-selective therapeutics, targeted-therapies prevent tumorigenesis through 
identifying and restraining specific molecular-targets. These include transduction pathways, 
specific proteins related to cancer progression, or through the stimulation of the immune system 
aiding in the delivery of cytotoxic drugs (Perez-Herrero & Fernandez-Medarde, 2015). Such 
treatments can prevent the growth, progression and spread of cancer-cells. Oncogenes, tumour-
suppressor genes and the completion of the human genome sequence have assisted in the 
understanding of the foundations of cancer initiation and progression, which can be capitalised 
upon to research beneficial targets in the battle against cancer (Jones, et al., 2016). Precision 
medicine isolates and centres treatment on the specific abnormalities of cancer-cells and 
therefore aims to reduce the number and severity of side effects associated with the general 
treatments commonly administered today (Hait, 2009).  
Cancer occurs when there is a substantial change in the cells genetic identity which modifies the 
cells molecular programming preventing healthy functioning. It is the distinctive molecular 
changes initiating cancer development which researchers are interested in as this molecular-
marker can act as the target for potential therapies (Wilson, et al., 2018). 
Targeted-therapies are not a new concept, however, there has been a dramatic peak of interest 
in the subject over the years. From a literature search on PubMed using the inputs of ‘cancer-‘ 
or ‘ovarian cancer- AND targeted therapies’ the surge in publications from 1ϵϳϳ until now is 
evident as illustrated in Figures 1.4 and 1.5 (National Center for Biotechnology Information, 
2019). However, what is also apparent from both figures is publications decreased from 2017 to 
present by 73% and 2016 to present by 75% respectively. Although this is not a direct 
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representation for the development of new targeted-therapies, it does suggest interest in the 
topic could be wane. While there are targeted-therapies available, they are limited to certain 
sub-types of cancer, meaning many individuals will not be eligible for the precision medicine 
available; this alone is a convincing reason as to why research needs to continue to find such 
unique markers within cancer to develop more direct treatments.  
Figure 1.4. Cancer and targeted therapy publication rate. The number of articles deposited in PubMed 
per year from 1977 to 2019. Data collected using search input ‘cancer AND targeted therapies’.  
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Figure 1.5. Ovarian cancer and targeted therapy publication rate. The number of articles deposited in 
PubMed per year from 1ϵϳϳ to 201ϵ. Data collected using search input ‘ovarian cancer AND targeted 
therapies’.  
Trastuzumab (Herceptin) is a targeted-therapy developed through the identification of some 
breast-cancers distinctively overexpressing the HER2 protein involved in extensive cell 
proliferation (Risi, et al., 2018). Dr D.Salmon identified the amplification of the HER2/neu gene 
in 30% of the 189 primary human breast-cancers investigated with an amplification of 2- to 20- 
fold (Slamon, et al., 1987). This was supported by Dr W.Gullick, however, with the use of 
immunohistological staining and Western Blotting, Dr Gullick established that the HER2 protein 
was also overexpressed in 33% of the HER2 gene emphasised breast-cancers (Gullick, et al., 
1987). In agreement, it was established that HER2 was in fact a worthy target in treating HER2 
positive breast-cancer. Through this important research, Dr Ullrich and Dr Shepard at Genentech 
developed an antibody which blocked the receptor activity of HER2; this drug was trastuzumab. 
Initial clinical trials started in 1992 with 15 women which expanded to 900 women by 1996 
eventually leading to the fast-tracked approval by the U.S Food and Drug Administration (FDA) 
(Harries & Smith, 2002). Herceptin is now a mainstream treatment for patients with HER2 
positive breast-cancer through research identifying a molecular-target creating a vulnerability 
for the cancer.  
With respect to OC more specifically, one targeted-therapy approved by the National Institute 
of Health Care and Excellence is olaparib (Lynparza) (National Institure for Health and Care 
Excellence , 2016). This drug is used as a maintenance therapy for OC patients with platinum 
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sensitivity. Eligibility for this drug involves the cancer patient having a mutation in their BRCA1 
or BRCA2 gene whilst also having had 3 or more courses of platinum based therapy (Robson, et 
al., 2017). Olaparib inhibits the ability of PARP to repair single stranded DNA breaks (Morales, et 
al., 2016) thus leading to cell death (Lin & Kraus, 2017). However, cells must have faulty BRCA 
genes to procure the full impact of the PARP inhibitor otherwise cells are less susceptible to the 
inhibitory effects and increases cells survival (as explored in Section 1.3). It is for this reason that 
patients receiving this treatment must have faulty BRCA genes (Chandna, 2019). 
Numerous studies have illustrated the benefits of using olaparib as a maintenance drug for 
advanced, platinum sensitive OC. Ledermann et al 2012, carried out a randomised, double-
blinded phase 2 study with 265 OC patients. 136 patients were assigned to 400mg of olaparib 
twice daily whilst 129 were assigned a placebo. Results showed that median PFS was 8.4 months 
vs 4.8 months respectively (Ledermann, et al., 2012). This is supported by Oza et al 2015, who 
compared olaparib, paclitaxel and carboplatin with paclitaxel and carboplatin alone; results 
showed PFS was significantly higher in the group treated with olaparib (median 12.2 months vs 
9.6 months respectively; p-value=0.0012) (Oza, et al., 2015).  
For precision medicines to be developed, a target within the cancer must be identified and 
exploited which does limit the number of patients who will benefit from the potential drug. This 
is why it is important to not look at certain cancers as a singular disease but instead study the 
individual histotypes and their unique targets. For OC, PARP and VEGF inhibitors are the 
precision medicines currently available; however, these are limited to those with faulty BRCA 
genes or high expression levels of VEGF-A (Goel & Mercurio, 2013). As previously mentioned, 
EGFR is expressed in up to 90% of certain OC histotypes (Wilken, et al., 2012) while also 
overexpressed in the SK-OV-3 cell line; with its crucial role in cell proliferation, migration and 
invasion, the receptor becomes a compelling target to explore for potential inhibitors in OC 
patients who overexpress EGFR (Wang, et al., 2016). Research has highlighted a positive result 
in targeting this receptor for the likes of non-small cell lung-cancer and pancreatic-cancer with 
gefitinib (Hirsch, et al., 2018) and erlotinib (Wang, et al., 2015). Unfortunately, these results are 
not yet mirrored for OC. However, further investigations need to be aroused into finding 
alternative, unorthodox therapies which have the potential to target unique marks such as EGFR. 
One route into novel, targeted-therapies which needs to be explored deeper is the use of 
anticancer venom peptides.  
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1.5. Natural Sources and Venom Constituents; Their Potential in Drug 
Development  
Throughout history, natural sources have been utilised to treat a number of diseases and 
infections since ancient times and in folklore (Dar, et al., 2017). The first records, written on clay 
tablets in cuneiform, are from Mesopotamia and date back to 2600 B.C. Such records evidenced 
the use of oils collected from Cupressus sempervirens and Commiphora myrrha which were used 
to treat colds, coughs and bronchitis (Dias, et al., 2012). Moreover, Egyptian medicine recorded 
in the Ebers Papyrus from 1500 B.C documents 700 drugs primarily sourced from plants; these 
range from ointments, to pills and infusions (Cragg & Newman, 2005). Drawing back to the 
beginning of the 21st century, 11% of the 252 drugs considered as basic and essential by the 
World Health Organisation (WHO) were in fact from plant origin (World Health Organisation, 
2020). It is therefore no surprise that natural sources remain a popular area of investigation in 
the drug discovery sector.  
Anticancer activity is another area in which natural sources have played a significant role. 
Terrestrial plants, the marine environment, microbes and slime molds are some of the natural 
sources with anticancer activity (Desai, et al., 2008). Paclitaxel, known as Taxol, is a microtubule-
stabilizing drug utilised in the treatment of numerous cancer including ovarian, breast, lung and 
pancreatic cancer (Zein, et al., 2019). This plant alkaloid was first isolated from Taxus brevifolia 
(pacific yew) in 1971 and approved for medical use in 1993 (Weaver, 2014). In addition to 
terrestrial plant sources, the marine environment also contains anticancer potential. 
Ecteinascidin-743, also known as Yondelis, is an extract from the sea squirt Ecteinascidia 
turbinata and is used to treat advanced soft tissue sarcoma through inhibiting the transcription 
of protein-coding genes (Tumini, et al., 2018). Ultimately, this is just a snapshot of the 
significance natural sources have had with respect to cancer therapeutics.  
As previously articulated, the treatment options available for OC are not only limited but are 
subject to several side effects, poor clinical outcomes and have restricted long-term success due 
to chemoresistance (Kim, et al., 2018). Investigations into finding alternative, novel and 
targeted-therapies has never been more applicable. Although a variety of targeted-therapies 
have been discovered and are used with varying successes for a variety of cancers (Section 1.4.2) 
there is still a shortage for OC making research in this field fundamental (Cortez, et al., 2018). 
Therefore, it has never been more relevant to explore the depths that natural sources have to 
offer which is why the anticancer activity of animal venoms is an essential step into finding 
alternative and novel therapeutics.  
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Venoms are a complex mixture of many biologically active compounds; proteins, peptides, 
enzymes and toxins contribute to the sophisticated cocktail (Williams, et al., 2019). Not all 
venomous animals contain the exact same composition of elements in their venom and will vary 
according to species, age, sex and geographical location (Tasoulis & Isbister, 2017). In natural 
settings, venom is utilised to either defend or hunt, which is why the arrangement of compounds 
in venoms have been selected by evolution to most beneficially impact the animal in its 
preferred environment (Trim & Trim, 2013). Natural selection has highlighted the specificity that 
venom toxins have for molecular-targets to ensure a desirable effect is achieved on the predator 
or prey whilst optimising the species energy expenditure (Casewell, et al., 2013). Such toxins can 
be classified depending on their specific biological effect; these include cytotoxins, neurotoxins, 
cardiotoxins and hemotoxins (Shanbhag, 2015). Depending upon their mode of action, it is 
possible to exploit certain venom components in the development of therapeutic agents.  
Unfortunately, research into the potential venom has in the therapeutic community has been 
restricted, researchers lacked the applicable equipment and methods in analysing the minuscule 
amounts of venom secreted by animals in a laboratory setting. However, with huge advances in 
omics analysis as well as innovations in bioinformatics and computational biology, exploring the 
capabilities of venoms and their diversification has never been more accessible (Utkin, 2017). 
This has not only aided in the FDA approval of 6 venom-based drugs and 3 more venom derived 
peptides in clinical trials, but also the plethora of research investigating the anticancer 
properties of venom (Pennington, et al., 2018).  
Song et al 2012, found that snake venom toxin from Vipera lebetina turanica (not yet identified) 
inhibited OC cell growth dose-dependently with an inhibitory concentration (IC50) of 4.5µg/ml 
in PA-1 cells and 6.5µg/ml in SK-OV-3 cells. Furthermore, apoptotic cell death was induced in 
these cell lines through inhibiting the NF-kB and STAT3 signal whilst also hindering P50 and P65 
translocation to the nucleus. In addition to this, the snake venom toxin also increased the 
expression of pro-apoptotic proteins Bax and caspase-3 and downregulating the anti-apoptotic 
protein Bcl-2 (Song, et al., 2012). Similarly, Chiu et al 2009, identified that the 60-amino-acid 
polypeptide residue cardiotoxin III (CTX III) isolated from Naja naja atra venom downregulated 
NF-kB in the human breast-cancer cell line MCF-7, which by extension inhibited proliferation 
and prompted apoptosis. Sub-G1 formation, PARP cleavage and phosphatidylserine 
externalisation established such results. This was achieved at an IC50 of 2µg/ml (Chiu, et al., 
2009). Moreover, Su et al 2010, indicated CTX III inhibited the phosphorylation of EGFR which 
prevented the activation of the JAK/STAT and PI3K/AKT signalling pathways (mentioned in 
Section 1.3) ultimately stimulating apoptosis in human adenocarcinoma A549 cells (Su, et al., 
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2010). However, CTX III is a cardiotoxin and is known to cause direct myocardial damage which 
can result in arrhythmias, bradycardia, tachycardia or hypotension; this means further 
investigations into the potential side effects this toxin could offer is required before drug 
development, as well as identifying the active anticancer constituent that is not cardiotoxic 
(Campbell & Cohall, 2017). As well as snake venom, scorpion venom also presents anticancer 
activity. Diaz-Garcia et al 2013, using an MTT assay identified venom from Rhopalurus junceus 
(R.jun) reduced cell viability significantly of epithelial cancer-cells at an IC50 ranging between 
0.6-1mg/ml. Furthermore, this scorpion venom induced apoptosis in Hela cells through 
overexpression of p53 and Bax mRNA, increase in caspases 3, 8, and 9 and downregulation of 
bcl-2 mRNA (Diaz-Garcia, et al., 2013) 
Anticancer properties of venom are not only utilised for their direct effect on particular cancer-
cells, but certain venom peptides can be utilised to aid in the detection of cancer. Recently, a 
novel imaging technique has been developed which employs the use of a synthesised form of 
scorpion venom which ‘lights up’ brain tumours, empowering neurosurgeons to identify 
malignant growths with greater superiority. Researchers from Cedars-Sinai led the phase 1 
clinical trial involving glioma patients; Tozuleristide (BLZ-100), which is composed of a synthetic 
chlorotoxin peptide found in scorpion venom, was attached to infrared-fluorophore-
indocyanine-green (fluorescent dye) and administered to 17 patients intravenously receiving 
doses between 3 and 30mg. Results showed tumour identification was significantly clearer using 
the Tozuleristide drug including both high-grade and low-grade gliomas; moreover, patients did 
not present serious adverse responses to the drug when monitored for 30 days after the trial 
(Patil, et al., 2019).  
Not all venoms will have anticancer properties nor will the same effect that occurred in one cell 
line necessarily be imitated in another cell line. Giovannini et al 2017, identified that the Vidatox-
30-CH drug, derived from the R.jun scorpion venom induced proliferation in hepatocellular 
carcinoma cells significantly when rats were treated for 30 days in comparison to the control 
group of rats identified using immune-staining for Ki-67 (p-value=0.01) (Giovannini, et al., 2017). 
However, venom from this same scorpion did prove to reduce cell viability in epithelial cancer-
cells, as previously mentioned, but did not affect hematopoietic tumour-cells (Diaz-Garcia, et 
al., 2013) illustrating the varied outcomes possible when used in different combinations. 
Although cytotoxic abilities of venom present specificity which ultimately limits the number of 
cancer types which will benefit from the effects, it does highlight that the venom must be 
targeting explicit molecular mechanisms and pathways. This further demonstrates why utilising 
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venom as a novel, targeted-therapy would be beneficial considering its particularity for cancer 
progression mechanisms.  
This snap-shot of research exemplified illustrates the vast prospective that venom has in a 
variety of cancers and the huge potential still unfilled. As documented, venom can interfere with 
cell signalling pathways imperative for cancer progression, as well downregulating and/or 
upregulating necessary proteins which initiate apoptosis and cancer-cell degradation. 
Moreover, significant peptides or proteins can be isolated and synthesised to be utilised 
synergistically alongside current treatments at lower doses increasing their effectiveness and 
limiting toxicity. It is however important to remember that cancer is a genetic disease with a 
unique amalgamation of genetic changes, therefore cancer-cells, even if they arise from the 
same area, will still vary significantly amongst each other. For this reason, venoms from the same 
species, even the same peptides, proteins or toxins will not automatically affect all cancer-cells 
the same way.  Consequently, it is essential that researchers not only identify and isolate specific 
proteins with cytotoxic capabilities, but also find the optimal venom-to-cancer coalition. This 
will aid in developing a panel of specific venom proteins that target distinct cancer types and 
molecular mechanism, essentially supporting the developments of novel therapies combatting 
the life-altering disease.  
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1.6. Conclusion  
OC contributes to the greatest number of deaths in regards to gynaecological diseases and is the 
sixth most common cancer in association with the UK female population. Non-targeted 
therapies that are currently employed and contribute to the optimal treatment plan are 
becoming increasingly ineffective. With 75% of OC cases being diagnosed at stages III and IV as 
well as chemoresistance preventing the long-term success of standard treatments, the hugely 
negative statistics associated with the disease comes as no surprise. With this in mind, it is 
imperative for the discipline of drug development to delve into research concerning alternative 
and unconventional therapies in order to overcome the barriers associated with successfully 
treating the disease. As established, the scientific literature available is abundant in 
investigations into the potential venoms have in a variety of diseases. Such research has allowed 
for the FDA approval of 6 venom-based drugs which have contributed to the management of 
cardiovascular diseases and chronic pain. Furthermore, contemporary investigations evident in 
the published literature have highlighted the number of successes occurring in the laboratory 
setting in relation to the anticancer properties of venom. Through the targeting of particular 
receptors as well as the upregulation and/or downregulation of certain proteins which are 
detrimental to the survival of cancer, the capability of certain venoms in relation to particular 
cancers are endless. As previously touched upon, the effects certain proteins and peptides have 
on one cancer will not necessarily be imitated in another type of cancer as well as among cancer 
histotypes which demonstrates the venoms specificity.  
For such reasons, the following project of investigating the effects of animal venoms in OC has 
been employed to contribute to the unconventional, novel therapeutics community. OC is 
associated with incredibly negative statistics and the number of women surviving the disease is 
not decreasing. With the technology currently available and the grounding research establishing 
the huge benefits that animal venoms can have, this investigation carried out has the potential 
to improve those statistics and the hope in finding a valuable treatment for OC.  
Using an assortment of crude and fractioned venoms at a range of doses utilising the resazurin 
assay, the cell viability of SK-OV-3 cells will be measured. This will aid in determining a profile of 
venoms at specific concentrations which have the ability to prevent SK-OV-3 cell metabolism. 
Furthermore, venoms which do not significantly affect cell viability can also be characterised 
into a profile and can be considered as redundant. Predominantly, the investigation can set the 
ground work for future perspectives. Venoms which are considered as hits can be easily 
identified and analysed further (i.e fractioned further to identify the specific proteins causing 
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the effect) whilst the venoms which are classed as redundant, in relation to SK-OV-3 cells, can 
be steered away from thus producing a groundwork in future investigations.  
Overall, the aims of this project are to:  
x Optimise the cell number of the SK-OV-3 cell line in the setting of a 96 well plate 
resazurin-based assay. 
x Optimise the positive control in regards to the optimal SK-OV-3 cell number, whilst in 
the setting of a 96 well plate resazurin-based assay. 
x Identify a number of crude and fractioned venoms that significantly reduce the cell 
metabolism of SK-OV-3 cells.   
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INVESTIGATING THE EFFECTS OF ANIMAL VENOMS IN OVARIAN CANCER 
CHAPTER TWO ʹ GENERAL MATERIALS AND METHODS  
2.1. Cell Line, Culture and Maintenance  
2.1.1. SK-OV-3 Cell Line  
Throughout this study, the Human ovarian cancer cell line SK-OV-3 was used. The cell line was 
derived from the ovary epithelium of a 64-year-old Caucasian female suffering from HGSOC; this 
specific cell line also significantly overexpresses the EGFR (Paramee, et al., 2018). The cell line 
was available from laboratory stocks which were originally sourced from the American Type 
Culture Collection (American Type Culture Collection, 2019). This cell line was authenticated by 
the European Collection of Authenticated Cell Culture using short tandem repeat profiling in 
March 2018 showing that the profiles match 100%.  
2.1.2. Routine Cell Culture and Maintenance  
All cell culture-based work was carried out under sterile conditions in a cell culture flow hood 
(MSC AdvantageTM – Thermo Fisher, UK); 70% industrial methylated spirit (IMS) was used to 
sterilise equipment entering the flow hood and any substances applied to the cells were warmed 
before application.  
SK-OV-3 cells were cultured as cohesive monolayers in both T25 (25cm3) and T75 (75cm3) cell 
culture flasks. Cells were maintained in Dulbecco’s Modified Eagles Medium (DMEM) which was 
supplemented with 10% Foetal Calf Serum (FCS), 1% Penicillin Streptomycin and 1% L-Glutamine 
(collectively known as media) (Thermo Fisher, UK). All cells were routinely incubated at 37°C, 
95% air and 5% CO2 (HERAcell 150i, Thermo Fisher, UK).  
Introduction of the first cryotube containing 1ml of SK-OV-3 cells was thawed at room 
temperature on the workbench before the contents were transferred to a T25 flask containing 
5ml of media. Once cells had settled (approximately 5 hours) the media was changed due to the 
presence of dimethyl sulfoxide (DMSO) in the freezing media.  
Sub-culturing occurred when cells were approximately 70% confluent and were usually split in 
a 1:2 or 1:3 ratio as recommended (ATCC, 2019). Media was removed from the flask and cells 
were washed with phosphate-buffered saline (PBS) twice. 0.05% trypsin-ethylene diamine tetra 
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acetic acid (trypsin-EDTA) was used to dissociate the cells; flasks were then returned to the 
incubator for a maximum of 10 min. Once cells had dislodged from the flask and depending on 
the cell split ratio, media was applied to the flask to collect the cells (pipetting up and down to 
reduce cell clumps) and appropriately aliquoted into new cell culture flasks containing fresh 
media. Depending upon the size of the cell culture flask used (T25 and T75 – Thermo Fisher, UK), 
volumes of media, PBS, trypsin-EDTA and DMSO/FCS varied; refer to Table 2.1 for clarification. 
Table 2.1.  Depending upon the size of flask used, varying volumes of standard contents applied to the 
cells varied. This included cell culture media aiding in cell growth, PBS to wash the cells, trypsin-EDTA to 
split the cells and DMSO/FCS used to freeze the cells.  
 
 
 
 
 
2.1.3. Freezing Stocks  
SK-OV-3 cells were frozen down to ensure continuous stocks of the cell line were available. Once 
cells had reached 80% confluency (increased confluency to account for any cells lost during 
cryopreservation process), routine cell culture protocol was followed, however, the addition of 
10% DMSO/90% FCS was used to collect the dislodged cells and transfer contents to sterile 
cryotubes (Thermo Fisher, UK). Stocks were frozen down in a 1:1 ratio (one flask to one 
cryotube). Cryotubes were slowly frozen, initially placed in the -20°C freezer for 20 min. before 
being transferred to the -80°C freezer (this is to ensure the cells were gradually frozen 
preventing ice crystal formation (Chaytor, et al., 2012)). A number of stocks were also stored in 
liquid nitrogen for permanent storage. 
 
 
 
Contents Flask Size 
 T25 Flask T75 Flask 
Media 5ml 15ml 
PBS 2ml 5ml 
Trypsin-EDTA 0.2ml 0.5ml 
DMSO/FCS 1ml 1.2ml 
 
32 
2.2 Cell Viability Resazurin Assay  
Resazurin, an oxidation-reduction indicator, was used to assess cell viability. This was utilised to 
evaluate the cell viability of SK-OV-3 cells when exposed to different animal venoms and at 
varying concentrations. Assays were executed over a 2-day period. Day 1 consisted of combining 
several flasks ready to be counted and plated into a 96 well plate (Thermo Fisher, UK). Day 2 the 
venom (Venomtech Ltd, UK) was prepared by diluting the stock with PBS for the desired working 
concentration before the application to the cells. Resazurin (Thermo Fisher, UK) was also 
prepared on day 2 by diluting the stock concentration with a known volume of media for the 
desired working concentration before the plate was analysed and the data collected.   
2.2.1. Day One: Harvesting and Plating Generic Protocol  
To harvest the cells, several T75 flasks at 80% confluency were combined to be counted. This 
procedure followed the standard protocol for sub-culturing as stated in Section 2.1.2 up until 
the incubation period in trypsin. After 10 min. in the incubator, 2ml of media was added into 
each flask and all contents were transferred and combined in a 15ml falcon tube (Thermo Fisher, 
UK). Cells were thoroughly pipetted up and down to disband any cellular clumps.  
20µl of the combined cells, 12µl of PBS and 8µl of trypan blue were transferred to a 0.5ml 
Eppendorf tube (Thermo Fisher, UK), again pipetting up and down to certify the cells were evenly 
dispersed before counting. Following this, a haemocytometer (Fisher Scientific, UK) was cleaned 
using 70% IMS and prepared by placing a glass coverslip over the counting chambers. The 
haemocytometer has two counting chambers, both of which consist of 9 squares. Cell counting 
involved the 4 corner squares of 1 chamber only.  
Once the haemocytometer was prepared, the cells were counted. This involved transferring 20µl 
of the contents in the Eppendorf tube into one side of the haemocytometer under the coverslip; 
through capillary action, the cells were drawn into the counting chamber ready to be counted. 
At this point, the cells in the falcon tube were stored at 4°C to prevent cells from settling whilst 
counting occurred. Using an inverted microscope (Leica, UK), cells were counted at 10x 
magnification. All cells inside the 4 corners were counted; the rule ‘top left in’ was utilised to 
ensure all cells were only counted once and to guarantee counts were consistent. Cells which 
were stained blue were not counted; this was an indication that the membrane was not intact 
and therefore cells were not viable. Once all cells were counted, the calculations exemplified in 
Figure 2.1 were used to determine if there were enough cells present to continue with the assay 
and by extension the volume per well required for the particular cell number desired.  
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Figure 2.1. The calculations utilised to find the cells per ml, total number of cells and the volume per well 
required. 
Upon determining the volume per well required, the combined cells were collected from the 
fridge. Cells were pipetted up and down before being transferred to a 50ml reservoir (Thermo 
Fisher, UK), this ensured cells were evenly dispersed in the media before application to the 96 
well plate. The required volume per well of cells was transferred to the 96 well plate according 
to the layout of the specific assay. The plate was then returned to the incubator overnight 
allowing the cells to adhere. 
2.2.2. Day Two: Venom and Resazurin Application Generic Protocol  
Day 2 of the assay consisted of first applying the required concentration and species of venom 
over a 2hour period, and then applying 160µM resazurin to the cells to determine the cell 
viability through measuring the fluorescence. Stock concentrations of venom were diluted with 
PBS whilst resazurin was diluted with media to make the required working concentrations. 
After approximately 24 hours (and the cells adhering to the plate), the media from all wells was 
removed and discarded. Again, depending on the assay being performed, the media was 
replaced with 50µl of venom (to the positive wells) or 50µl of PBS (to the negative wells). Ensuing 
venom application, the plate was returned to the incubator for 2 hours.  
During incubation time, the FLUOstar Omega Microplate reader (BMG Labtech, UK) was 
prepared and the working concentration of resazurin was made. To prepare the plate reader, 
Cell count calculation: 
1. Average number of cells 
- Total number of cells counted / number of corners counted 
2. Cells per ml 
- 2 x average number of cells x 104 
3. Total number of cells 
- Cells per ml x total volume* 
4. Volume per well 
- Cell number required / cells per ml 
*total volume added to combine cells. 
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the protocol ‘resazurin fluo bottom͛ was selected and the temperature was set to 37°C. 
Parameters included an excitation of 544, emission of 590 and gain of 800 with a 90% target 
value. Formulating the resazurin involved diluting the stock concentration of 1.6mM to the 
working concentration of 160µM with a known volume of media. The volume of resazurin 
required was dependent on the number of wells in use.  
Subsequent to the 2 hour incubation time, the PBS and venom was removed and replaced with 
50µl of the 160µM resazurin. The fluorescence of the plate was then measured every 15 min. 
for 1 hour, followed by every 30 min. for the following 4 hours. The raw data was stored using 
the MARS Data Analysis Software (BMG Labtech, UK) and processed using Microsoft Excel 2016 
or GraphPad Prism 5.    
2.3. Resazurin Assay – Z Prime  
The Z prime (Z’) assay was utilised throughout the optimisation protocols in order to determine 
assay quality and robustness. This type of assay is commonly used in high-throughput screening 
to assess whether the response in a particular assay is great enough to permit further attention. 
The Z’ assay produces a Z-factor which describes how well separated the positive and negative 
controls are through processing the means and standard deviations of the data; this helps to 
eliminate the likelihood of false positives and negatives in the results.  A Z-factor between 0.5-1 
represents an excellent assay as this indicates there is a large separation band between the 
positive and negative means exhibiting a difference in the controls. Below 0.5 suggests the assay 
is not robust and therefore does not pass due to a small or overlapping separation band. This 
type of assay was consequently used to ensure conclusions drawn from the optimisation assays 
were robust enough to continue with, as well as determining the optimal time point to which 
the plate should be analysed (Zhang, et al., 1999).  
The Z’ assay was set up as described in Chapter 2.2 in regards to counting and plating cells on 
day 1, followed by venom and resazurin application on day 2 as well as data collection. The assay 
layout remained consistent throughout the project; the 96 well plate was divided into four 
quadrants. The positive controls (venom) were located opposite one another in the top left and 
bottom right quadrants of the plate. Likewise, the negative controls (PBS) were also positioned 
opposite one another in the bottom left and top right quadrants of the plate. This is done to 
eliminate the ‘edge effect’.  
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After 2 hours of incubation in either venom or PBS, all contents were removed and replaced 
with 160µM resazurin. The fluorescence of the plate was then measured and data analysed as 
described in Section 2.2.2.  
2.4. Resazurin Assay – Dose Response  
Dose responses (DR’s) were performed on the various venoms throughout the project to 
investigate lethal doses (LD). This assay was used throughout the optimisation process and 
during the introduction of test compounds.  
Again, following the same protocol described in Chapter 2.2, the cells were plated on day 1 and 
left to adhere overnight whilst day 2 consisted of applying the venom and resazurin. In addition 
to day 2 and before venom application, a compound plate was set up to aid in the serial dilution 
of the venom and to simplify the transfer of venom to the test plate. Column 1 of the compound 
plate contained the highest concentration of venom, this was serially diluted by half across the 
plate in PBS. Positive and negative controls were allocated to columns 11 and 12 respectively.  
Upon completing the compound plate, the media from the test plate was removed and replaced 
with 50µl of the corresponding contents in the compound plate. The test plate was then 
returned to the incubator for 2 hours as per standard protocol. Following this, all contents were 
removed from the plate and replaced with 160µM resazurin and analysed as outlined in Section 
2.2.2.  
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INVESTIGATING THE EFFECTS OF ANIMAL VENOMS IN OVARIAN CANCER 
CHAPTER THREE ʹ OPTIMISATION OF RESAZURIN ASSAY 
3.1. Aims  
The following experiments were utilised to optimise the resazurin assay before the introduction 
of test compounds. First, the optimal cell density of SK-OV-3 cells was investigated to compare 
a variety of different cell densities and thus find the cell number which produced the maximum 
assay window. This window demonstrates the fold change between the positive and negative 
controls, thus the larger the window the greater the difference is between the controls. The 
optimal cell density should have a window high enough that it produces a measurable signal, 
nevertheless, overcrowding must be avoided. Following this, a DR was carried out on the crude 
Naja nigricollis (N.nig) venom to find the LD90 and thus solidify the positive control for the 
forthcoming test assays; this provides a baseline with which the results from test compounds 
can be compared and validated. Finally, Z’ assays were implemented to calculate a Z-factor 
which measures assay quality and therefore determines the robustness of the assay before 
moving forward as explained in Section 2.3.  
3.2 Background 
Resazurin assays are a fluorometric assay which have the aptitude to determine the metabolic 
ability of active cells in a high throughput setting through the reduction of non-fluorescent 
resazurin to highly fluorescent resorufin. The higher the fluorescence, the more metabolically 
active cells present. Such assays are commonly used within drug discovery due to their high 
throughput capabilities, it is therefore important to optimise the assay ensuring its high 
sensitivity and prompt result production enabling a robust and reliable system (Kim & Jang, 
2017).  Furthermore, assays of this sort are commonly used to determine cell viability and the 
proliferation capacity in eukaryotic cells. Walzl et al 2014, utilised the resazurin assay to 
distinguish between cytotoxic and cytostatic compounds in several colonic cancer cell lines 
(Walzl, et al., 2014) whilst Ricigliano et al 2017, using a resazurin assay, investigated the most 
effective third line of treatment for pancreatic adenocarcinoma patients (Ricigliano, et al., 2017). 
Moreover, Czekanska 2011, assessed the effectiveness of resazurin assays for cell viability and 
cell proliferation investigation; it was determined that the assay utilises all features of an ideal 
and reliable test whilst it is sensitive, safe, non-toxic to cells and extremely cost effective 
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(Czekanska, 2011). Such examples validate the effectiveness of the resazurin assay in terms of 
investigating cell viability and establish it is a fitting assay for this investigation.  
3.3 Methods 
3.3.1. Optimisation of SK-OV-3 Cell Number 
3.3.1.1. 100µg/ml N.nig Venom 
3.3.1.1.1. Method 
Amongst the literature, investigations involving the SK-OV-3 cell line and cell viability assays 
showed that a cell density ranging from 104 to 105 were used (Attar, et al., 2017, Chan, et al., 
2003). It was the interest of this experiment to test a range of cell densities relevant to the 
literature available. 4 cell densities consisting of 2x105, 1x105, 5x104 and 2.5x104 number of cells 
were therefore explored.  
100µg/ml N.nig venom (diluted from a stock concentration using PBS) was initially used as the 
positive control and PBS dedicated to the negative control. As illustrated in Table 3.1, the highest 
cell density was plated at the top with decreasing densities down the plate. Each cell number 
had 12 replicates which were divided into 6 positive, and 6 negative repeats. Following standard 
procedure explained in Section 2.2, cells were plated on day 1 whilst the venom and resazurin 
was applied on day 2. The fluorescence of the plate was then measured every 15 min. for 1 hour 
followed by every 30 min. for the following 4 hours.  
Table 3.1. Plate layout for optimisation of cell number. Rows A, C, E and G were the positive controls and 
therefore had 50µl of the 100µg/ml N.nig venom applied. Rows B, D, F and H were the negative controls 
and therefore had 50µl of PBS applied.  
  1 2 3 4 5 6 7 8 9 10 11 12 
A 2x105 2x105 2x105 2x105 2x105 2x105             
B 2x105 2x105 2x105 2x105 2x105 2x105             
C 1x105 1x105 1x105 1x105 1x105 1x105             
D 1x105 1x105 1x105 1x105 1x105 1x105             
E 5x104 5x104 5x104 5x104 5x104 5x104             
F 5x104 5x104 5x104 5x104 5x104 5x104             
G 2.5x104 2.5x104 2.5x104 2.5x104 2.5x104 2.5x104             
H 2.5x104 2.5x104 2.5x104 2.5x104 2.5x104 2.5x104             
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To analyse the data, an average of the fluorescence at each time point for the cell numbers 
including the positive and negative control were taken. A fold change at each time point was 
then calculated by dividing the average negative control by the average positive control. The 
graph of window (y-axis) against time point (x-axis) was then plotted for each cell number. As 
previously stated, the larger the window the greater the difference is between the positive and 
negative controls. 
3.3.1.1.2. Results and Discussion  
From the results, illustrated in Figure 3.1, it is clear that the 100µg/ml N.nig venom used did not 
prevent cell metabolism at the two highest cell densities (2x105 and 1x105). This is evident as the 
window for both cell densities does not reach above 2 suggesting there is a small difference 
between the positive and negative control. The highest window is achieved by the smallest cell 
density of 2.5x104 which reaches a window of 14 after 300 min. Unfortunately, the fold change 
produced by the cell numbers using 100µg/ml crude N.nig venom suggests a measurable signal 
would not be produced. Although 2.5x104 produces the greatest window overtime, this is not 
achieved until 5 hours which is not an ideal length of time to read the plate. Due to such reasons, 
no cell density could be considered as ‘optimal’ and therefore the experiment needed repeating.  
Figure 3.1. The processed data of the SK-OV-3 cell number optimisation assay using 100µg/ml N.nig 
venom (positive control) and PBS (negative control). The graph illustrates the fold change between the 
positive and negative control over a 5 hour period for the cell densities 2x105, 1x105, 5x104 and 2.5x104. 
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3.3.1.2. Investigating Higher Concentrations of Venom for the Positive 
Control – 200Pg/ml and 500Pg/ml N.nig Venom 
3.3.1.2.1. Method 
Following the previous results, the experiment was repeated with the same intention of finding 
the optimal cell density of SK-OV-3. As previously described, 100µg/ml N.nig venom did not 
prevent cell metabolism, therefore the concentration of venom used was increased by 2- and 5- 
fold to ensure cell metabolism across all cell densities were reduced. The same cell densities 
used in the previous assay were investigated as explained in Section 3.3.1.1. This time the plate 
was separated into 2 distinct sections, the left side dedicated to 200µg/ml and the right side 
dedicated to 500µg/ml N.nig venom.  
As illustrated in Table 3.2, cell densities were plated from highest to lowest down the plate. Each 
cell density had 10 replicates (for each venom concentration) which were divided into 5 positive 
controls and 5 negative controls. Following standard procedure, cells were plated on day 1 whilst 
the venom and resazurin were applied on day 2. The fluorescence of the plate was then 
measured every 15 min. for 1 hour followed by every 30 min. for the following 4 hours.  
Table 3.2. Plate layout for optimisation of cell number. Rows A, C, E and G were the positive controls and 
therefore had 50µl of either 200µg/ml N.nig venom or 500µg/ml N.nig venom applied. Rows B, D, F and 
H were the negative controls and therefore had 50µl of PBS applied. Columns 6 and 7 have been removed 
from the plate layout illustrated as they remained empty throughout the assay.  
 
 
 
 200µg/ml 500µg/ml 
  1 2 3 4 5 8 9 10 11 12 
A 2x105 2x105 2x105 2x105 2x105 2x105 2x105 2x105 2x105 2x105 
B 2x105 2x105 2x105 2x105 2x105 2x105 2x105 2x105 2x105 2x105 
C 1x105 1x105 1x105 1x105 1x105 1x105 1x105 1x105 1x105 1x105 
D 1x105 1x105 1x105 1x105 1x105 1x105 1x105 1x105 1x105 1x105 
E 5x104 5x104 5x104 5x104 5x104 5x104 5x104 5x104 5x104 5x104 
F 5x104 5x104 5x104 5x104 5x104 5x104 5x104 5x104 5x104 5x104 
G 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
H 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
2.5x10
4 
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3.3.1.2.2. Results and Discussion  
500Pg/ml:  
Data was processed as described in the previous cell number optimisation assay. As illustrated 
in Figure 3.2, it is clear that the N.nig venom at a concentration of 500µg/ml reduced cell 
metabolism as the window between the positive and negative controls across all cell densities 
were marginally greater in comparison to the previous assay. 2x105 achieved the greatest 
window of 28.44 at 60 min. before gradually decreasing. 1x105 achieved a maximum window of 
25.98 at 120 min before gradually decreasing, however, 1x105 attained the greatest window 
until 210 min. 5x104 and 2.5x104 also have improved fold changes reaching a window in the high 
teens after 120 min. and 210 min. respectively, in addition 5x104 after 240 min. achieved the 
greatest window.  
 
 
 
 
 
 
 
 
 
Figure 3.2. The processed data of the SK-OV-3 cell number optimisation assay using 500µg/ml N.nig 
venom (positive control) and PBS (negative control). The graph illustrates the fold change between the 
positive and negative control over a 5 hour period for the cell densities 2x105, 1x105, 5x104 and 2.5x104.  
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200µg/ml: 
As illustrated in Figure 3.3, 200µg/ml N.nig venom also reduced cell metabolism across all cell 
densities. Parallel to the previous assay, the greatest window is achieved by 2x105 reaching 27.88 
after 90 min. before gradually decreasing for the duration of the assay. Once again, 1x105 
reaches a maximum window of 27.09 at 120 min. which is the greatest window at that time 
point. This cell density continues to have the greatest window until 240 min. whereby 5x104 
takes over. Both 5x104 and 2.5x104 achieve a more gradual increase in window overtime in a 
similar way when dosing the cells with 500µg/ml reaching maximum windows of 22.14 after 240 
min. and 20.83 after 270 min. respectively.  
 
 
 
 
 
 
 
 
 
 
Figure 3.3. The processed data of the SK-OV-3 cell number optimisation assay using 200µg/ml N.nig 
venom (positive control) and PBS (negative control). The graph illustrates the fold change between the 
positive and negative control over a 5 hour period for the cell densities 2x105, 1x105, 5x104 and 2.5x104.  
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As mentioned, 2x105 and 1x105 number of cells presented the greatest fold changes over time, 
however, 1x105 number of cells presented a more gradual increase in window whereas 2x105 
number of cells contributed a much sharper increase; this means subtle changes in the test 
assays could potentially be missed using the higher cell number due to the sharp increase. 
Furthermore, by using the cell density of 1x105 relative to 2x105 less flasks would be required to 
perform the assay and by extension a shorter time period of growth is required to prepare the 
cells. With the most compelling argument, it was decided that the optimal cell density to move 
forward with was 1x105.  
When considering the optimal cell density, the greatest window achieved, the time taken to 
reach that window, the venom concentration utilised and number of flasks required were 
considered. Firstly, both concentrations investigated in this assay reduced cell metabolism 
across all densities. As less venom from the stock concentration was required to make the 
working concentration of 200µg/ml, it was logical to focus on this concentration ensuring venom 
stocks were not wasted, therefore the fold change results associated with 200µg/ml were 
further analysed in deciding the optimal cell number. As explained, 2x105 produced the greatest 
window relative to the other cell densities, however this window is achieved rather rapidly with 
a sharp increase in window in only 45-90 min. where the cell density peaks and gradually 
decreases. As there is such a rapid increase, subtle results produced in test assays could 
potentially be missed due to the sharp increase. On the other hand, 1x105 represented a more 
gradual increase in window overtime and achieved the greatest window after 120 min. to 240 
min. whereby 5x104 seized the maximum window. As 1x105 represents a more steady increase 
subtle changes in test assay are more likely to be witnessed, furthermore, using this cell number 
required the cultivation of less flasks which again prevents wasting materials. Although, as 
mentioned, 5x104 attains the maximum window after 240 min. this is not an ideal time to read 
the plate whereas 120 min. is a more reasonable time to analyse the assay. In summary, with 
the reasons listed here the most compelling, optimal cell density is 1x105 number of cells and 
was therefore utilised in subsequent assays. In regards to current research in association with 
SK-OV-3 and resazurin based assays, cell densities used range from 5x104 to 4x105 which are 
fitting with the optimal cell density identified here (Jiang, et al., 2009, Chan, et al., 2003).  
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3.3.2. Z’ Assay for the Optimal Cell Number  
3.3.2.1. Method 
The Z’ assay was utilised to generate a Z-factor for the previous optimal cell density assay to 
demonstrate the robustness of using 1x105 cells in the subsequent assays. On day 1, 1x105 cells 
were plated across all 96 wells on the plate. The following day the plate was divided into 4 
quadrants as described in Section 2.3; 2 quadrants were dedicated to the positive control, 
200µg/ml N.nig venom, whilst the other 2 quadrants were dedicated to the negative control, 
PBS. This layout is illustrated in Table 3.3. The plate was analysed following standard protocol 
(Section 2.2.2).  
Table 3.3. Plate layout of the Z’ assay used to test the robustness of the optimal SK-OV-3 cell number 
chosen, 1x105. On day 1, 1x105 cells were plated across all 96 wells. On day 2, the plate was split into four 
quadrants, two dedicated to the positive control and two dedicated to the negative control. Controls were 
located opposite each other. 50µl of 200µg/ml N.nig venom was applied to the positive wells and 50µl of 
PBS was applied to the negative wells.  
 
3.3.2.2. Results and Discussion  
From the raw data collected, the fold change was processed first (as described in Section 
3.3.1.1.1) to determine the window between the positive and negative controls and to also 
ensure this assay was in agreement with the previous optimal cell density assay. From Figure 
3.4, it is clear that the results are consistent with those of the previous assay in Section 3.3.1.2.2. 
This agreement is displayed with the gradual increase in fold change overtime reaching a 
window of 26 after 120 min. whereby the fold change begins to steadily decrease.  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A + + + + + + - - - - - - 
B + + + + + + - - - - - - 
C + + + + + + - - - - - - 
D + + + + + + - - - - - - 
E - - - - - - + + + + + + 
F - - - - - - + + + + + + 
G - - - - - - + + + + + + 
H - - - - - - + + + + + + 
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Figure 3.4. The processed data of the Z’ Assay for the optimal SK-OV-3 cell number 1x105. The graph 
illustrates the fold change between the positive control (200µg/ml N.nig venom) and the negative control 
(PBS) over a 5 hour period.  
Ensuing this, the Z-factor was calculated. The Z-factor is defined in terms of the means (µ) and 
standard deviations (𝜎) of the positive (p) and negative (n) controls and is calculated using the 
following equation: 
𝑍𝑓𝑎𝑐𝑡𝑜𝑟 ൌ 1 െ 
3ሺ𝜎𝑝 ൅ 𝜎𝑛ሻ
|𝜇𝑝 െ 𝜇𝑛|
 
An average of the positive and negative controls were taken at each time point, thus a Z-factor 
at each time point was calculated. From this a graph of Z-factor (y-axis) against time (x-axis) was 
plotted as exemplified in Figure 3.5. As confirmed, a Z-factor between 0.5-1 indicates an 
excellent assay and is therefore considered as robust. A Z-factor below 0.5 (marginal assay) or 0 
(poor assay) implies the assay is not robust (Doherty, et al., 2011).  It is therefore promising to 
see at time point 0 min., the Z-factor is 0.52 as illustrated in Table A.1 in the appendix. The Z-
factor continues to increase reaching highs of 0.96 after 150 min. This signifies an excellent assay 
and suggests the use of 1x105 number of cells is robust enough to move forward with. Such 
results can now be used as a ground work for future research when using the SK-OV-3 cell 
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number and venom-based compounds in the setting of a resazurin assay as the optimal cell 
density has been identified.  
Figure 3.5. The processed data of the Z’ Assay for the optimal SK-OV-3 cell number 1x105. The graph 
illustrates the calculated Z-factor over a 5 hour period.  
3.3.3. Dose Response of N.nig Venom  
3.3.3.1. Method 
A DR curve of the N.nig venom was produced with the purpose of finding the LD90 (dose 
required to kill 90% of the population) and thus solidify the positive control utilised for the 
subsequent assays involving the test compounds. Table 3.4 demonstrates the layout of the assay 
plate. 1x105 number of SK-OV-3 cells were plated on day 1 and returned to the incubator 
overnight as per standard protocol established in Section 2.2. 
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Table 3.4. The layout of the assay plate required for the DR of the N.nig venom. Each column had 5 
replicates of 1x105 SK-OV-3 cells.  
 
The following day a compound plate was constructed to serially dilute the crude N.nig venom 
before the application to the assay plate. To do this, 500µg/ml N.nig venom was applied to 
column 1, rows A,B and C. In columns 2 to 12, rows A,B and C, 120µl of PBS was applied as 
illustrated in Table 3.5.a. In order to serially dilute the venom by 1:2, 120µl of contents in column 
1 were transferred to column 2 and thoroughly mixed. 120µl of the contents in column 2 were 
then transferred to column 3 and thoroughly mixed. This was repeated across the plate until 
column 11. A key has been constructed as shown in Table 3.5.b which specifies the 
concentration in each column after the serial dilution. 
Table 3.5.a. A colour coded layout of the compound plate used to serial dilute the N.nig venom. 
Column 1 contained 240Pl of 500Pg/ml and columns 2 to 12 contained 120Pl of PBS. The venom was 
then serially diluted by 1:2 across the plate until column 11; column 12 was dedicated to the negative 
control containing PBS only. Definitively, columns 1 to 10, and 12 (row a, b and c) contained a final 
volume of 120Pl, whilst column 11 (row a,  b and c) contained a final volume of 240Pl.  
 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
B 1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
C 1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
D 1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
E 1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
F             
G             
H             
  1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B                         
C                         
D                         
E                         
F                         
G                         
H                         
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Table 3.5.b. A colour coded key corresponding to the concentration of N.nig venom in each column. 
Starting at 500µg/ml in column 1 and diluting by half each time reaching the lowest concentration of 
0.488µg/ml in column 11. The negative control was PBS, therefore only PBS was allocated to column 12.  
KEY 
  500.00µg/ml 
  250.00µg/ml 
  125.00µg/ml 
  62.50µg/ml 
  31.25µg/ml 
  15.63µg/ml 
  7.81µg/ml 
  3.91µg/ml 
  1.95µg/ml 
  0.98µg/ml 
  0.49µg/ml 
  Cells and PBS only 
 
Upon completing the compound plate, the media was removed from the assay plate and 
replaced with 50µl of the contents in the corresponding wells of the compound plate i.e. 
contents of column 1 of compound plate into column 1 of assay plate. As established in the key, 
column 12 was allocated as the negative control, therefore 50µl of PBS was applied to cells in 
the column. The assay plate was then returned to the incubator for 2 hours before the 
application of 160µM resazurin and the plate fluorescence was measured following standard 
procedure in Section 2.2.2.  
The data was collated and processed to produce a DR curve; from this curve the LD90 of the 
N.nig could be deduced. A DR curve is a plot of the percent inhibition (y-axis) against the Log10 
of the chemical concentration (x-axis). Firstly, an average of the fluorescence for each 
concentration across all time points was taken as well as the Log10 of the concentration. From 
this, the percentage of growth was calculated using the equation: %𝐺𝑟𝑜𝑤𝑡ℎ ൌ ቀ ி
ெி
ቁ 𝑥 100 
whereby ‘F’ is the fluorescence of the concentration of interest (i.e. the average fluorescence at 
ϱ00ђg/ml) and ‘MF’ is the maximum fluorescence (i.e. the average of the negative control, PBS). 
Once the percentage of growth was calculated, the percentage of inhibition could be 
considered. This was done by using the equation: %𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 ൌ 100 െ %𝐺𝑟𝑜𝑤𝑡ℎ. The DR 
curve was then plotted with Log10 of the concentration on the x-axis and percent of inhibition 
on the y-axis with a line of best fit. From the y-axis, a horizontal straight line can be inserted 
from 90% inhibition to the line of best fit which can then be extended by a vertical line to the x-
axis to find the Log10 of the concentration which causes 90% inhibition. Taking the exponential 
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of the Log10 concentration required to cause 90% inhibition then calculates the actual 
concentration of the N.nig venom in µg/ml.  
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3.3.3.2. Results and Discussion  
Once the raw data was processed the graph, illustrated in Figure 3.6, was constructed as 
explained in the previous section. Using the line of best fit, the concentration required to inhibit 
90% of cell metabolism was determined. In this case, at 90% inhibition, the log10 concentration 
of N.nig venom was 1.42, therefore 101.42 resulted in 26.92Pg/ml and is the calculated LD90. To 
test the robustness of this value and solidify the optimised positive control for the forthcoming 
venom assays, a Z-factor was analysed to statistically confirm the positive control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. The DR curve produced for the N.nig venom to find the LD90. Raw data was processed and 
averaged over a 5 hour period.  
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Moreover, this experiment clarified a batch variation issue in relation to the first vial of N.nig 
crude venom used in Section 3.3.1.1. From the results of that experiment, it was clear that the 
N.nig venom at 100Pg/ml did not reduce cell metabolism. This prompted the increase in venom 
concentration in the second cell density optimisation assay in Section 3.3.1.2 to 200Pg/ml and 
500Pg/ml. This conceivably suggests that the initial batch of venom used was not as active as 
the subsequent batches. The most probable cause for this batch variation could be due to the 
number of freeze-thaw cycles. Morrison et al 1983, identified that 10 freeze-thaw cycles of 
Tropidechis carinatus (elapid) venom resulted in a loss of activity by 9% (Morrison, et al., 1983) 
whilst Bloom et al 1998, acknowledged that Chironex fleckeri (box jellyfish) venom lost activity 
after 2 freeze-thaw cycles (Bloom, et al., 1998).  
To reiterate, results expressed here set the foundation for forthcoming assays in the present 
work carried out and for future investigation. Resazurin based assays utilising the SK-OV-3 cell 
line and investigating the cytotoxic effects of venom can ultimately refer to optimisation 
processes and results outlined here to obtain not only the optimal cell density but also the 
positive control.  
3.3.4. Z’ Assay for the LDϵ0 of N.nig  venom  
3.3.4.1. Method 
Similar to the previous Z’ assay, the experiment was utilised to calculate the Z-factor and 
determine whether the LD90 of N.nig venom was robust enough to move forward with as the 
positive control. As per the standard protocol (Section 2.2.1), 1x105 number of SK-OV-3 cells 
were plated across the 96 well plate on day 1 and returned to the incubator. On day 2, all 
contents from the wells were removed and the plate was divided into 4 quadrants; 2 dedicated 
to PBS only (negative control) and 2 dedicated to 26.92µg/ml N.nig venom as shown Table 3.6. 
Matching controls were diagonally opposite one another to avoid the edge effect. Once the 
controls were applied to the cells, the plate was returned to the incubator for 2 hours. 
Proceeding this, all contents were removed once again before the application of 160µM 
resazurin and the plate was analysed using the plate reader following standard protocol (Section 
2.2.2).  
 
 
 
51 
Table 3.6. 1x105 number of cells were plated across the 96 well plate on day 1. The following day the 
controls were applied, 50Pl of PBS as the negative control, and 50Pl of 26.92Pg/ml N.nig venom as the 
positive control.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A + + + + + + - - - - - - 
B + + + + + + - - - - - - 
C + + + + + + - - - - - - 
D + + + + + + - - - - - - 
E - - - - - - + + + + + + 
F - - - - - - + + + + + + 
G - - - - - - + + + + + + 
H - - - - - - + + + + + + 
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3.3.4.2. Results and Discussion  
The fold change of the cell number was processed first to establish that there was a great enough 
window between the positive and negative control. Figure 3.7 demonstrates that the fold 
change followed a similar pattern to the previous assay in Section 3.3.2. There is a steady 
increase in window which reached highs of 19.9 after 120 min. before gradually decreasing.  
Figure 3.7. The processed data of the Z’ assay 4.0 for the LDϵ0 of N.nig crude venom. The graph illustrates 
the fold change between the positive control (26.92µg/ml N.nig venom) and the negative control (PBS) 
over a 5 hour period.  
Following this, the Z-factor was calculated using the equation expressed in Section 3.3.2.2 and 
articulated in graphical form. Referring to Figure 3.8, it is clear that the LD90 selected as the 
positive control was robust; after 15 min. a Z-factor of 0.61 was achieved which continued to 
increase up until 0.91 at time point 120 min. before gradually decreasing. This indicates an 
excellent assay solidifying the positive control. In addition to this, the data also reveals that the 
optimal time to read the fluorescence of the plate is 120 min as this produced the greatest Z-
factor.  
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Figure 3.8. The processed data of the Z’ assay for the LDϵ0 of N.nig crude venom. The graph illustrates 
the calculated Z-factor over a 5 hour period.  
Although the results here illustrate that the assay was robust, this was not the first Z’ assay 
utilised, instead this was the fourth attempt. The Z-factor results of the first Z’ assay is illustrated 
in Figure A.1 in the appendix. Results illustrate that over a 5 hour period, a Z-factor above 0.5 is 
not achieved rendering the assay as a poor assay and not robust. However, upon analysing the 
raw data illustrated in Figure A.2, the positive control demonstrated a great deal of variation. 
Due to this variation the calculated means of the positive and negative control were too similar 
reducing the separation window causing the positive and negative controls to overlap thus 
producing a low Z-factor score (GraphPad, 2010).  
The Z’ assay was repeated a second time, this time a full ϵϲ well plate was used increasing the 
number of replicates (as opposed to Z’ assay 1.0 which used 64 wells only). Furthermore, to 
overcome variation in the negative control, cells were pipetted up and down multiple times in 
the reservoir before being aliquoted into the wells; this was done to reduce cellular clumps. If 
cells were clumped together when plating occurred, there would be more than 1x105 number 
of cells in the well therefore the surplus SK-OV-3 cells not inhibited by the venom can reduce 
resazurin thus explaining one cause of the variation. Although Z-factor results improved, as 
illustrated in Figure A.3, a Z-factor above 0.5 was only achieved between 30 and 90 min before 
returning to a poor assay. Investigating the raw data, illustrated in Figure A.4, there was still 
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variation within the negative control which by extension calculated means for the positive and 
negative control which were too similar thus resulting in a low Z-factor.  
The Z’ assay was carried out for a third attempt. This time the venom and resazurin were both 
pipetted up and down before application to the cells as well as pipetting the cells up and down. 
This was done to ensure the protein composition in the venom was evenly dispersed amongst 
the cells. This ensured inhibitory capabilities of the venom were evenly dispersed as well as 
certifying uniform levels of resazurin were applied to the cells allowing for similar reduction 
rates of resazurin to occur. The results of the Z-factor produced from the third assay are 
illustrated in Figure A.5. Over the 5 hour period, a Z-factor above 0 was not achieved, once again 
signifying the assay as poor and not robust. This time the raw data, exemplified in Figure A.6, 
demonstrated that there were 7 wells amongst the negative control which produced a great 
deal of variation suggesting less metabolism was occurring in these wells compared to the 
positive control. As the Z-factor is sensitive to the variability in the positive and negative control, 
a Z-factor above 0.5 was not achieved (Boveia, et al., 2009). A possibility as to why this occurred 
could be due to adhesion of the plate not being as strong resulting in cells being removed when 
discarding media and venom; however, this was ultimately unexplained during the time of the 
investigation, therefore a fourth Z’ assay was carried which produced a Z-factor above 0.5 for 
the duration of the assay and therefore considering 26.92µg/ml as a robust positive control.  
Alongside determining the Z-factor for the LD90 of N.nig venom (as established in Section 3.3.3), 
GraphPad Prism 5 was also utilised to statistically confirm the LD90 of the venom. Using 
nonlinear regression analysis, dose-response special of Find ECanything and setting the F 
constraint to 90%, the LD90 (ECF) was determined as 24.13µg/ml, as illustrated in Table A.2. 
Unfortunately, this was not done until after utilising test compounds, however the Z-factor 
produced identified that 26.92µg/ml N.nig venom was an acceptable and robust LD90. 
Therefore, to remain consistent throughout experiments, 26.92µg/ml N.nig was set as the 
positive control. 
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INVESTIGATING THE EFFECTS OF ANIMAL VENOMS IN OVARIAN CANCER 
CHAPTER FOUR ʹ OPTIMISED VENOM ASSAYS 
4.1. Aims  
After optimising the parameters for the resazurin assay, the test compounds were introduced. 
Such compounds included venoms from a variety of species both crude and fractioned using 
high pressure liquid chromatography (HPLC). Crude venom of Parabuthus transvaalicus (P.tra ʹ 
scorpion), Heterometrus madraspatensis (H.mad ʹ scorpion) and Heterometrus mysorensis 
(H.mye - scoprion) were exploited. Fractioned venom comprised of N.nig, Agkistrodon contortrix 
pictigaster (A.cpi – viper snake), Poecilotheria regalis (P.reg – spider) and Pandinus cavimanus 
(P.cav – scorpion). The venom was then utilised in the setting of a DR assay which determined if 
a certain venom significantly reduced SK-OV-3 cell metabolism and to what extent metabolism 
was reduced (in terms of percent inhibition). An arbitrary threshold was considered throughout 
the assays and employed to determine if the venom was of significance; if the venom inhibited 
50% or more of cell metabolism, this would be considered as significant. Venoms of significance 
were then utilised further, this involved fractioning the venom to further analyse any significant 
proteins or peptides present which could then have the potential to be analysed further using 
mass spectrometry.  
4.2 Background 
A DR describes the way in which an organism responds to certain levels of exposure from a 
specific compound. In terms of drug development, a DR is an appropriate way of characterising 
‘hit’ compounds which affect an organism in a desired way (Blass, 2015). Moreover, DR 
relationships are important in assessing the efficacy and potency of drugs, whilst also a useful 
tool for the interpretation of drug and receptor interactions (Campbell & Cohall, 2017). In terms 
of this project, the DR was utilised to identify which venoms inhibited cell metabolism of SK-OV-
3 cells. Through dosing the cells with a serial dilution of the venom and developing the DR curve, 
it is possible to eliminate venoms which do not reduce cell metabolism and identify venoms 
which successfully inhibit the cell metabolism. As previously touched upon, in order to 
determine whether a venom was of significance, a threshold of 50% was established, otherwise 
known as the median lethal dose (LD50). This is the dose required to kill 50% of a population 
after a specified test duration. As the LD50 is utilised in pharmacology to indicate a substances 
acute toxicity, it was fitting to use this threshold to categorise significant venoms and their acute 
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toxicity (Ng, 2004). Furthermore, although arbitrary, the threshold indicates that there is more 
cell inhibition than metabolism therefore highlighting itself as a logical cut-off.  
4.3 Methods 
4.3.1. Dose Response of Crude P.tra Venom  
Using crude P.tra venom, a DR was carried out to identify if the venom from this particular 
scorpion species had a significant effect on the cell metabolism of SK-OV-3 cells as well as 
detecting the LD50 of the venom.  
Following standard procedure in Section 2.2.1, 1x105 number of SK-OV-3 cells were plated on 
day 1 according to the plate layout established in Table 4.1. The plate was returned to the 
incubator overnight allowing cells to adhere. A compound plate was set up on the following day 
as demonstrated in Table 4.2 a-b; this was done to serially dilute the venom and simplify the 
application of venom to the test plate. Starting at a concentration of 200µg/ml, the venom was 
serially diluted by 1:2 as utilised in the previous assay illustrated in Section 3.3.3.1. Once the 
venom was appropriately diluted, the contents from the test plate were replaced by the 
corresponding contents in compound plate. The test plate was then returned to the incubator 
for 2 hours before replacing the contents with 160µM resazurin and analysing the plate. 
Table 4.1. The layout of the assay plate for the DR of P.tra scorpion venom. Each column had 5 replicates 
of 1x105 SK-OV-3 cells.  
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
B 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
C 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
D 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
E                         
F                         
G                         
H                         
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Table 4.2. 
a. A colour coded layout of the compound plate used to serially dilute the P.tra venom. Column 1 
contained 240µl of 200µg/ml P.tra venom whilst column 2 to 10 contained 120µl of PBS. The 
venom was then serially diluted by 1:2 across the plate as explained in Section 3.3.3.1. Column 11 
was dedicated to the positive control (26.92µg/ml N.nig crude venom) and column 12 was 
dedicated to the negative control (PBS). Definitively, columns 1 to 9, 11 and 12 (row a and b) 
contained a final volume of 120Pl, whilst column 10 (row a and b) contained a final volume of 
240Pl.  
  1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B                         
C                         
D                         
E                         
F                         
G                         
H                         
 
b. The colour coded key (to Table 4.2.a.) corresponding to the concentration of P.tra venom in each 
column. Starting at 200µg/ml in column 1 and diluting by half each time reaching the lowest 
concentration of 0.391µg/ml in column 10. The positive and negative control are situated in 
column 11 and 12.  
KEY 
  200.00µg/ml 
  100.00µg/ml 
  50.00µg/ml 
  25.00µg/ml 
  12.50µg/ml 
  6.25µg/ml 
  3.13µg/ml 
  1.56µg/ml 
  0.78µg/ml 
  0.39µg/ml 
  N.nig 26.92µg/ml 
  Cells and PBS only 
 
Results for the DR were processed at time point 120 min. in accordance to the Z’ assay results 
in Section 3.3.4.2. The data was processed as demonstrated in Section 3.3.3.1 and a graph of 
percent inhibition (y-axis) against Log10 of the concentration (x-axis) was constructed.   
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4.3.2. Dose Response of Crude H.mad and H.mye Venom  
With a similar aim to the previous assay, a DR was utilised to identify if the crude venom from 
H.mad and H.mye significantly reduced cell metabolism of the SK-OV-3 cell line as well as 
determining the LD50. The results from the previous DR illustrated that the scorpion venom was 
not potent enough at 200Pg/ml and therefore did not completely prevent cell metabolism of 
the SK-OV-3 cell line. Due to this, the highest venom concentrations of both H.mad and H.mye 
were increased to 500Pg/ml; this was done in the hope that the previous results were not 
repeated and a 100% inhibition rate was reached.  
Once again, cells were plated on day 1; 1x105 number of SK-OV-3 cells were applied to the 96 
well plate according to the plate layout in Table 4.3. The plate was then returned to the 
incubator overnight allowing the cells to adhere. Again, to set up the serial dilution and to 
simplify the application of venom to the test plate, a compound plate was employed. One 
compound plate was used to dilute both venoms; 2 rows were dedicated to H.mad and 2 rows 
were dedicated to H.mye. Both venoms started at a concentration of 500µg/ml which was 
serially diluted by 1:2 across the plate as represented in Table 4.4 a-b. When the compound 
plate was complete, the contents from the test plate were removed and replaced with the 
corresponding contents in the compound plate. The test plate was then returned to the 
incubator for 2 hours before applying the resazurin and analysing the plate as per Section 2.2.2.  
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Table 4.3. The plate layout for the DR of H.mad and H.mye venom. Rows A, B, C and D were dedicated to 
the H.mad venom whilst rows E, F, G and H were dedicated to the H.mye venom. Both venoms at each 
concentration had 4 replicates. The positive and negative controls were situated in columns 11 and 12 
respectively.  
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
B 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
C 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
D 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
E 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5     
F 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5     
G 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5     
H 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5     
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Table 4.4.  
a.  A colour coded layout of the compound plate used to serially dilute both H.mad and H.mye 
venom. Rows A and B were dedicated to H.mad whilst rows D and E were dedicated to 
H.mye. Column 1 contained 240µl of 500µg/ml H.mad and H.mye venom whilst columns 2 
to 10 contained 120µl of PBS. The venom was diluted by 1:2 across the plate according to 
Section 3.3.3.1. Column 11 and 12 contained the positive (26.92µg/ml N.nig crude venom) 
and negative (PBS) control respectively. Definitively, columns 1 to 9, 11 and 12 (rows a, b, d 
and e) contained a final volume of 120Pl, column 10 (rows a, b, d and e) contained a final 
volume of 240Pl.   
 
b. The colour coded key corresponding to the compound plate (table 5.4.a.) representing the 
concentration of venom in each column. Starting with the highest concentration of 
500µg/ml in column 1 and diluting this by half resulting in the lowest concentration of 
0.977µg/ml in column 10.  
KEY 
  500.00µg/ml 
  250.00µg/ml 
  125.00µg/ml 
  62.50µg/ml 
  31.25µg/ml 
  15.63µg/ml 
  7.81µg/ml 
  3.91µg/ml 
  1.95µg/ml 
  0.98µg/ml 
  N.nig 26.92µg/ml 
  Cells and PBS only 
 
 
 
 
   1 2 3 4 5 6 7 8 9 10 11 12 
H.mad A                         
B                         
 C                         
H.mye D                         E                         
 F                         
 G                         
 H                         
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4.3.3. Dosing with Venom Fractions  
Dosing the cells with a panel of venom fractions was utilised to identify not only significant 
species which reduced SK-OV-3 cell metabolism, but also find particular fractions from those 
species which significantly impacted cell metabolism. Species involved in the venom fraction 
assay included N.nig, A.cpi, P.reg and P.cav.  
As per standard set up, 1x105 number of SK-OV-3 cells were plated across 3 identical 96 well 
plates to create 3 replicates for each venom fraction. All 3 plates were returned to the incubator 
overnight allowing the cells to adhere. On day 2, the compound plate and resazurin 
concentrations were prepared before application to the cells. A readymade compound plate was 
provided by Venomtech (Venomtech Ltd, UK) with a plate layout established in Table 4.5. 
Venomtech fractioned the venoms and prepared the plate. Venoms were fractioned by reverse 
phase HPLC and were quantified using UV microspectrophotometry and standardised at 6µg per 
well, using a DS11, in a v-bottom, low protein binding 96 well plate. Using antistatic matting in 
the flow hood (to prevent loss of protein) venom fractions were resuspended in 200µl of PBS 
and left at room temperature for 5min; this was done to ensure complete rehydration of the 
venom. As there was 6µg of protein per well and with the addition of 200µl of PBS, the final 
concentration of each venom fraction was 30µg/ml ( ଺µ௚
ଶ00µ௟
 𝑥 1000 ൌ 30µ𝑔/𝑚𝑙). 26.92µg/ml 
N.nig (positive control) and PBS (negative control) were applied to the last 4 wells of column 12 
of the compound plate also.  
Once the venom fractions were rehydrated, all media was removed and discarded from the 3 
test plates before transferring 50µl of the contents in the compound plate to the corresponding 
wells of the 3 test plates. All test plates were then returned to the incubator for 2 hours. After 2 
hours, all contents from the 3 plates were removed and replaced with 160µM resazurin before 
the plates were analysed and data collected. 
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Table 4.5. The layout of the readymade compound plate supplied by Venomtech Ltd. Each well contained 
a volume of 200µl at a concentration of 30µg/ml. 50µl of each well was transferred to 3 tests plates with 
the exact same layout. 200µl of the positive control (26.92µg/ml crude N.nig; column 12, row E and F) and 
negative control (PBS; column 12, row G and H) were applied to the plate also.  
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Data was processed at the 120 min. time point in accordance with the results from the Z’ assay 
in Section 3.3.4.2. Firstly, the percentage of inhibition was calculated for each plate individually 
as done in Section 3.3.3.1. Then, the average percent inhibition was calculated across all 3 plates 
and a graph of percent inhibition (y-axis) against venom fraction (x-axis) was plotted. Following 
this an arbitrary threshold of 50% was set, this meant that any fractions with percent inhibition 
of 50% or more were carried forward for statistical analysis using a t-test. Fractions with a p-
value of 0.05 or less were considered as a significant fraction in reducing cell metabolism and 
were therefore explored further in induvial DR’s.  
4.3.4. Dose Response of N.nig_r11 Fraction  
Following statistical analysis described in Section 4.4 (Table 4.11), it was determined that the 
N.nig_r11 fraction was of significance in reducing cell metabolism of SK-OV-3 cells. It was already 
identified that this fraction was of significance at a concentration of 30µg/ml, therefore a DR 
initiated at 200µg/ml was utilised to find the LD50 of the venom as previously done.  
As previously undertaken, 1x105 number of SK-OV-3 cells were plated on day 1 as shown in Table 
4.7 before the plate was returned to the incubator overnight. The following day, the compound 
plate utilised to serially dilute the venom was set up, this is illustrated in Table 4.8 a-b. The 
highest concentration of the N.nig_r11 fraction used was 200µg/ml. Once the venom was 
appropriately diluted, the contents from the test plate were replaced with the respective 
contents in the compound plate. The test plate was returned to the incubator for 2 hours. 
Subsequent to this, contents from the test plate were once again replaced with 160µM resazurin 
and the plate was analysed as explained in Section 2.2.2.  
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Table 4.7. The layout of the assay plate for the DR of the N.nig_r11 venom fraction. Each column 
contained 5 replicates of 1x105 SK-OV-3 cells.  
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
B 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
C 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
D 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
E 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
F                         
G                         
H                         
 
Table 4.8.  
a.  A colour coded layout of the compound plate used to serially dilute the N.nig_r11 venom 
fraction. Column 1 contained 240µl of the highest concentration of venom starting at 200µg/ml. 
Columns 2 to 10 contained 120µl of PBS which was utilised to dilute the venom by 1:2 across the 
plate. The positive control (26.92µg/ml crude N.nig venom) and negative control (PBS) were 
dedicated to columns 11 and 12 respectively. Definitively, columns 1 to 9, 11 and 12 (rows a, b 
and c) contained a final volume of 120Pl, whilst column 11 (rows a, b and c) contained a final 
volume of 240Pl.  
 
 
 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B                         
C                         
D                         
E                         
F                         
G                         
H                         
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b. The colour coded key corresponding to the compound plate (Table 4.8.a.) representing the 
concentration of venom in each column. Starting with the highest concentration of 200µg/ml in 
column 1 and diluting this by half resulting in the lowest concentration of 0.391µg/ml in column 
10.  
KEY 
  200.00µg/ml 
  100.00µg/ml 
  50.00µg/ml 
  25.00µg/ml 
  12.50µg/ml 
  6.25µg/ml 
  3.13µg/ml 
  1.56µg/ml 
  0.78µg/ml 
  0.39µg/ml 
  N.nig 26.92µg/ml 
  Cells and PBS only 
 
GraphPad Prism 5 was used to calculate the LD50 of the fraction. Using nonlinear regression 
analysis, dose response stimulation of log(agonist) vs. normalised response determined the 
concentration which inhibited 50% of cell metabolism. 
4.3.5. Dose Response of P.cav_r28 Fraction  
Like that of the previous experiment, P.cav_r28 fraction was considered as a significant fraction 
in inhibiting SK-OV-3 cell metabolism; therefore, the fraction was analysed further in the setting 
of a DR to determine the LD50.  
In accordance to standard protocol outlined in Section 2.2, 1x105 number of SK-OV-3 cells were 
plated on day 1 as illustrated in Table 4.9. The plate was returned to the incubator overnight 
allowing the cells to adhere. The following day, the compound plate was set up as illustrated in 
Table 4.10 a-b. Unfortunately, there were limited stocks of the P.cav_r28 fraction therefore the 
maximum concentration utilised in this experiment was 15.63µg/ml. Upon completing the 
compound plate, contents from the test plate were removed and replaced with the 
corresponding contents in the compound plate. The test plate was returned to the incubator for 
2 hours before replacing the contents with 160µM resazurin and analysing the plate as per 
Section 2.2.2.  
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Table 4.9. The layout of the assay plate for the DR of the P.cav_r28 venom fraction. Each column 
contained 4 replicates of 1x105 SK-OV-3 cells. 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
B 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
C 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
D 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
1x10
5 
E             
F                         
G                         
H                         
 
Table 4.10  
a. The colour coded layout of the compound plate used to serially dilute the P.cav_r28 fraction. 
Column 1 contained 240µl of 15.63µg/ml P.cav_r28 fraction whilst columns 2 to 10 contained 
120µl of PBS. The venom was diluted across the plate by 1:2. Column 11 contained the positive 
control (26.92µg/ml crude N.nig venom) and column 12 contained the negative control (PBS). 
Definitively, columns 1 to 9, 11 and 12 (rows a and b) contained a final volume of 120Pl, whilst 
column 10 (rows a and b) contained a final volume of 240Pl.   
 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B                         
C                         
D                         
E                         
F                         
G                         
H                         
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b. The colour coded key corresponding to the compound plate (Table 4.10.a) representing the 
concentration of venom in each column. Starting with the highest concentration of 15.63µg/ml 
in column 1 and diluting this by half resulting in the lowest concentration of 0.03µg/ml in column 
10.   
KEY 
  15.63µg/ml 
  7.81µg/ml 
  3.91µg/ml 
  1.95µg/ml 
  0.98µg/ml 
  0.49µg/ml 
  0.24µg/ml 
  0.12µg/ml 
  0.06µg/ml 
  0.03µg/ml 
  N.nig 26.92µg/ml 
  Cells and PBS only 
 
4.4. Results  
The initial DR operated crude P.tra venom at a starting concentration of 200µg/ml. As illustrated 
in Figure 4.1, the venom inhibited SK-OV-3 cell metabolism by a maximum of 44.55% at the most 
concentrated dose of 200µg/ml. Although it is evident that the venom inhibited cell metabolism, 
the inhibition of significance threshold of 50% was not achieved, thus being an indication that 
this scorpion venom, at the specified concentration, does not significantly inhibit cell 
metabolism of the SK-OV-3 cell line.  Furthermore, the usual sigmoidal curve achieved using 
logistic functions is not represented at the beginning of the DR curve and instead fluctuates 
between 10% and 20%; it is not until 6.25µg/ml (Log10=0.80) whereby the positive correlation 
between the increase in venom concentration and increase in percent inhibition is attained.  
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Figure 4.1. The DR curve produced for the P.tra venom at 120 min. Raw data was processed and averaged 
over a 2.5 hour period.  
Following on from P.tra venom, the Heterometrus genus was investigated using crude H.mad 
and H.mye scorpion venom at an initial concentration of 500µg/ml. Clarified in Figures 4.2 and 
4.3 respectively, both venoms did not inhibit cell metabolism of the SK-OV-3 cell line to a 
significant extent. H.mad venom, displaying considerable variation, inhibited cell metabolism by 
an extremity of 0.78% at the most concentrated dose of 500µg/ml (Log10=2.70). Again, no clear 
relationship is established between venom dosing and inhibition of cell metabolism. Similarly, 
H.mye venom inhibited 2.35% of SK-OV-3 cell metabolism at the maximal concentration of 
500µg/ml whilst also exerting no positive relationship. Although H.mye inhibited cell 
metabolism to a greater extent compared to H.mad, the 50% threshold was not encountered by 
either venom which demonstrates that both venoms utilised at a concentration of 500µg/ml do 
not significantly inhibit cell metabolism and therefore are not considered as hits.  
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Figure 4.2. The DR curve produced for the H.mad venom at 120 min. Raw data was processed and 
averaged over a 3 hour period.  
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Figure 4.3. The DR curve produced for the H.mye venom at 120 min. Raw data was processed and 
averaged over a 3 hour period.  
Subsequent to the crude venom assays, a panel of fractioned venoms were investigated to 
assess the metabolic inhibitory extent of particular venom fractions relative to the SK-OV-3 cell 
line. Again, fractions achieving 50% inhibition or more were considered as significant hits. Of the 
92 fractions explored, 11 fractions exceeded the 50% inhibition threshold as validated in Figure 
4.4. These fractions were from species N.nig, P.reg and P.cav. To confirm the fractions were 
significantly reducing SK-OV-3 cell metabolism and to ensure only statistically significant 
fractions were pursued, a t-test was performed demonstrated in Table 4.1. This finalised that 
fractions N.nig_r11 (p-value=0.002), P.cav_r28 (p-value=0.028) and P.cav_r30 (p-value=0.036) 
were statistically positive hits in significantly reducing cell metabolism. Unfortunately, there 
were no stocks left of the P.cav_r30 fraction, therefore N.nig_r11 and P.cav_r28 were carried 
forward only.  
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Figure 4.4. The processed results from the DR of testing various venom fractions against cell metabolism 
of SK-OV-3. The bar graph illustrates the percent inhibition achieved by each fraction. Due to the size of 
the graph, the x-axis labelling is unclear, refer to Table A.3 in the appendix for clarification. Fractions left 
to right on the graph correspond to ordered fractions in Table A.3.  
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Table 4.11. The statistical results of the t-test used to find what fractions significantly impacted the cell 
metabolism of SK-OV-3 cells. From the arbitrary 50% threshold put in place, the fractions listed below had 
a percent inhibition of 50% or greater. They were therefore carried forward and a t-test was used to 
highlight the fraction above 50% which significantly reduced cell metabolism. From the t-test it is clear 
that N.nig_r11, P.cav_r28 and P.cav_r30 significantly reduced cell metabolism in the SK-OV-3 cell line. 
 
Using the N.nig_r11 venom fraction first, a DR, starting at a maximum concentration of 
200µg/ml, was performed to clarify the LD50. The processed data reflected in Figure 4.5, 
demonstrates that the N.nig_r11 fraction certainly inhibited the metabolic activity of SK-OV-3 
cells. 96.44% of cell metabolism was inhibited at the maximum venom concentration of 
200µg/ml whilst results also demonstrated the sigmoidal curve representing a relationship 
between increasing venom concentration and increase in percent inhibition. As mentioned in 
Section 4.3.4, GraphPad Prism 5 was used to calculate the LD50 of the fraction, as demonstrated 
in Table 4.12, results suggested a concentration of 37.23µg/ml (Log10=1.571) is required to 
inhibit cell metabolism by 50%.  
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Figure 4.5. The DR curve produced by the N.nig_r11 venom fraction at 120 min. Raw data was processed 
and averaged over a 3 hour period.  
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Table 4.12. The calculated LD50 of the N.nig_r11 venom fraction using GraphPad Prism ϱ. The ‘LOGECϱ0’ 
demonstrates the Log10 concentration of the LDϱ0 whilst ‘ECϱ0’ demonstrates the LDϱ0 in terms of 
µg/ml.  
log(agonist) vs. normalized response  
Best-fit values   
LOGEC50 1.571 
EC50 37.23 
Std. Error   
LOGEC50 0.2048 
95% Confidence Intervals   
LOGEC50 1.108 to 2.034 
EC50 12.82 to 108.2 
Goodness of Fit   
Degrees of Freedom 9 
R² 0.7796 
Absolute Sum of Squares 4639 
Sy.x 22.70 
Number of points   
Analyzed 10 
  
Following this, the P.cav_r28 fraction was investigated in the setting of a DR to also confirm the 
LD50. As explained in Section 4.3.5, stocks of the P.cav_r28 were extremely limited and could 
only be utilised at a maximum concentration of 15.63µg/ml. Results, represented in Figure 4.6, 
demonstrated that the venom inhibited an extremity of 2.54% of SK-OV-3 cell metabolism using 
the specified maximal concentration meaning the significant 50% inhibitory threshold was not 
accomplished. Ultimately, the venom starting at a concentration of 15.63µg/ml, does not reach 
the 50% threshold therefore the LD50 could not be considered.  
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Figure 4.6. The DR curve produced for the P.cav_r28 venom fraction at 120 min. Raw data was processed 
and averaged over a 2.5 hour period.  
Overall, the results suggest that the P.tra venom, although presenting inhibitory tendencies, did 
not reach the 50% threshold and can therefore not be considered as a positive hit at the 
specified concentration. In addition, H.mad and H.mye venom did not reach the 50% threshold 
even though the initial venom concentration utilised was increased to 500µg/ml. This suggests 
that both Heterometrus venoms do not present inhibitory abilities and are therefore considered 
as redundant. Comparing the scorpion venom, the results indicate that the Parabuthus venom 
inhibited SK-OV-3 cell metabolism more than the Heterometrus venom at a considerable 
decreased concentration. This fundamentally suggests there are specific proteins and peptides 
present in the P.tra venom which are absent from H.mad and H.mye venom that inhibit SK-OV-
3 cell growth. The cytotoxic potential of the Parabuthus and Heterometrus genus’ will be 
explored further in Section 5.1 as well as their assigned families. Likewise, from the P.cav_r28 
assay, it is clear the venom did not significantly reduce cell metabolism, however as mentioned, 
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the stocks of this fraction were limited resulting in a reduced concentration of the venom being 
utilised in the assay. Nevertheless, the venom, when used at 30µg/ml in the fraction dosing 
assay, did significantly inhibit cell metabolism. The following Section will therefore explore the 
cytotoxic capabilities of the Pandinus genus and the potential proteins and peptides specific to 
this venom which may have attributed to its original inhibitory aptitudes. Moreover, the results 
indicate that the N.nig_r11 fraction significantly inhibited cell metabolism of SK-OV-3 cells and 
is therefore regarded as a positive hit warranting further investigation. Again, the distinct 
proteins and peptides which contribute to the Naja genus and Elapidae family will be discussed. 
Furthermore, the possible mechanisms and signalling pathways, associated with SK-OV-3 
progressions, that were potentially inhibited by the aforementioned venoms will be considered 
in more depth.  
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INVESTIGATING THE EFFECTS OF ANIMAL VENOMS IN OVARIAN CANCER 
CHAPTER FIVE ʹ DISCUSSION 
5.1. Discussion 
Cancer as a whole is a major public health problem worldwide (Siegal, et al., 2019); 18 million 
new cases of cancer were presented in 2018 on a global scale followed by 9 million deaths 
(Ferlay, et al., 2018). Epithelial-OC is unfortunately a detrimental disease to the female 
population worldwide. The elusive symptoms associated with OC are commonly misdiagnosed 
for less serious conditions such as pre-menstrual syndrome (NHS, 2017), ultimately preventing 
the early diagnosis of the disease. The 5-year survival statistics in FIGO stages I and II is around 
90% in comparison to 30% for stages III and IV (Sartorius, et al., 2018); it therefore comes as no 
surprise that this illness is the deadliest of gynaecologic diseases when over 75% of OC patients 
are diagnosed at an advanced stage (Lomnytska, et al., 2018).  
Current standard of care for OC is surgical debulking supplemented by adjuvant chemotherapy, 
however, 70-80% of patients will develop chemoresistance within the first 2 years of therapy 
and require subsequent lines of treatment (Ventriglia, et al., 2018). This demonstrates that the 
‘one-size-fits-all’ approach is failing. Although research into targeted-therapies has been 
amplified over recent years, OC still lacks in successful precision medicines with PARP and VEGF 
inhibitors being the main therapies utilised (Vetter & Hays, 2018). This highlights the need to 
identify more molecular-targets in OC that can be exploited for the development of targeted-
therapies. With this in mind, there is a huge requirement to bridge the gap in the understanding 
of alternative, novel therapies which have the potential to be utilised in the treatment of OC. 
One area in contemporary research demonstrating a level of popularity in regards to oncology 
is the exploration of animal venoms and their anticancer properties. Such research, both in vitro 
and in vivo, has illustrated the benefits of using particular venoms to reduce cancer cell-growth 
and progression (Moga, et al., 2018).  
Consequently, it was the aim of this project to identify specific venoms that reduce cell viability 
of OC (in particular the SK-OV-3 cell line) and thus facilitate in building foundations for future 
developments in regards to innovative therapeutics. This ultimately enables improvements to 
the ability of treating OC. The research employed intended to identify what specific venoms, 
crude and fractioned, reduced the cell viability of SK-OV-3 cells and to what extent, in terms of 
concentration, said venoms prevented at least 50% of cell metabolism. This ultimately produced 
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a panel of venoms that can be characterised as positive hits (i.e reduce the metabolic activity of 
SK-OV-3 cells) or considered as redundant (i.e do not significantly affect the metabolic activity 
of SK-OV-3 cells). This was achieved through the use of resazurin based-assays in the setting of 
a DR to identify the percent of inhibition attained by the particular venoms used.  
P.tra was the initial crude venom analysed for its inhibitory effects. The results illustrated that 
the venom, at 200µg/ml, did not reach the 50% threshold (LD50) of inhibition in regards to 
metabolism of SK-OV-3 cells. Due to the venom not achieving the threshold at the specified 
concentration, it was characterised as redundant. Nevertheless, though the venom did not reach 
the threshold, inhibition at 200µg/ml reached 44.55%. This suggests P.tra venom does have 
inhibitory tendencies in relation to the SK-OV-3 cell line, however, the venom concentration 
used was somewhat too low. Diaz-Garcia et al 2013, investigated the inhibitory effects of the 
scorpion venom from R.jun against a panel of human cancer cell lines using an MTT assay. 
Results identified the lowest IC50 achieved by the venom was in accordance to the A549 cell line 
(lung carcinoma) of 630µg/ml. The highest IC50 achieved was from the Hela cell lines (cervix 
adenocarcinoma) reaching 1050µg/ml (Diaz-Garcia, et al., 2013). Unfortunately, literature 
regarding P.tra venom and cell viability assays are limited, however, the R.jun scorpion and P.tra 
originate from the same Buthidae family (NCBI, 2019).  Furthermore, Al-Asmari et al 2016, using 
Androctonus bicolor venom (another Buthidae member), achieved an LD50 for the MDA-MB-
231 (breast cancer) and HCT-8 (colorectal cancer) cell lines at 839µg/ml and 730µg/ml 
respectively (Al-Asmari, et al., 2016). Research such as this suggests venom of the Buthidae 
family presents cytotoxicity at considerably concentrated doses which ultimately implies 
increasing the concentration of P.tra venom would increase the cytotoxic ability and thus meet 
the 50% threshold. However, this does suggest the venom is less potent and would therefore be 
less useful as a drug; nevertheless, it is important to remember that the venom is crude and 
could potentially have components working antagonistically resulting in the need for an 
increased concentration. It is therefore a venom to still consider in characterising as a positive 
hit and warrants further investigation.  
The Buthidae family are the largest family of scorpions and contain a number of medically 
valuable species (White & Meier, 1995). P.tra is one of the species considered as therapeutically 
useful (Shah, et al., 2018). Research has established that scorpion venoms contain short-chain 
neurotoxins (SCNs), which act on potassium (K+) and chloride (Cl-) channels, and long-chain 
neurotoxins (LCNs), which mainly act on sodium (Na+) channels (Cologna, et al., 2009). Nisani et 
al 2011, using fast protein liquid chromatography and matrix-assisted laser 
desorption/ionisation-time of flight (MALDI-TOF) MS, identified a number of peptides present 
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within specific fractions of the P.tra venom. These included kurtoxin, parabutoxin, birtoxin, 
alitoxin, ikitoxin and dortoxin; such peptides have the aptitude to efficiently target Na+, K+, Cl- 
and calcium (Ca2+) channels (Nisani, et al., 2012). As mentioned, P.tra venom used in this 
investigation was crude, thus meaning a cocktail of the aforementioned peptides could have 
been present in the venom at varying concentrations therefore suggesting any one of those 
peptides individually or in pairing caused the inhibition of SK-OV-3 cells through acting upon ion 
channels.  
Kurtoxin, a 63 amino-acid peptide stabilised by 4 disulfide bonds, is known to inhibit T-type 
voltage-gated Ca2+ channels (TTVGCC); such channels have been associated with disease states 
such as hypertension and cancer, in particular OC. Calcium demonstrates an important role in 
intracellular signalling as well as controlling different cellular process such as proliferation, 
growth, differentiation and apoptosis (Humeau, et al., 2018); the intracellular level of calcium is 
regulated by TTVGCC (Kim, et al., 2018). Research has identified that these channels are 
commonly overexpressed in cancer-cells, especially OC, which in turn modulates cellular 
proliferation; moreover, when the channel was blocked using mibefradil or NNC 55-0396 
apoptotic cell death was induced (Li, et al., 2011). In accordance to this, Jang et al 2013, 
identified that KYSO5090 and its derivatives (T-type Ca2+ inhibitors) reduced cell metabolism 
significantly in SK-OV-3 and A2780 cells in the form of a cell viability assay (Jang, et al., 2013). 
Such research has established the importance of the TTVGCC in the progression of OC whilst 
demonstrating inhibition of this channel induces apoptosis and reduces cell viability. Considering 
an established TTVGCC inhibitor in P.tra venom, Kurtoxin, it is possible to suggest that this 
peptide could have been responsible for the inhibitory effects present in the venom in relation 
to SK-OV-3 cells.  
Another peptide from P.tra venom of value is Parabutoxin, a 37 amino-acid peptide, that inhibits 
voltage-gated K+ channels (VGPC) (Huys, et al., 2002). Once again, the channel plays a key role 
in proliferation of many tumour cells with researchers demonstrating its overexpression in 
cancers of the brain, breast, lung and ovary (Bielanska, et al., 2009). Of importance to this 
project, Asher et al 2010, identified that Eag (a K+ channel substrate) was overexpressed in the 
SK-OV-3 cell line using immunofluorescence and IHC which was significantly associated with 
poor survival (p-value=0.016). Furthermore, proliferation of SK-OV-3 cells was significantly 
reduced when treated with VGPC inhibitors (p-vaue<0.0001) (Asher, et al., 2010). Unfortunately, 
there is no published research relating to the direct inhibitory effects of Parabutoxin in 
accordance to specific tumours including SK-OV-3; however, the research presented is an 
indication of potential molecular targets in the SK-OV-3 cell line as well establishing that 
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inhibiting such channels induces apoptosis in cancer-cells. Parabutoxin can therefore be 
theorised as potentially targeting VGPC and thus reducing cell metabolism of SK-OV-3 cells.  
Birtoxin, alitoxin, ikitoxin and dortoxin are all toxins identified in P.tra venom which inhibit 
voltage-gated Na+ channels (VGSC). Like TTVGCC and VGPC, VGSC have been associated with the 
particular processes that lead to increased tumour aggressiveness and development in many 
cancers, and more specifically and of great concern, OC (Rhana, et al., 2017). VGSC are 
composed of nine members, NaV1.1 through to NaV1.9 encoded by genes SCN1A-SCN5A and 
SCN8A-SCN11A. Using RT-PCR, Gao et al 2010, identified that NaV- 1.2, 1.4, 1.5 and 1.7 were all 
overexpressed in the OC cell lines SK-OV-3 and Caov-3, however, NaV1.5 was expressed only in 
OC cells and absent from healthy cells using Western Blot analysis (Gao, et al., 2010). Utilising 
this, Liu et al 2018, using patch-clamp technique and RNA interference approaches not only 
identified the existence of NaV1.5 channels in SK-OV-3 but also acknowledged that 15µM of  
eicosapentaenoic acid (EPA – inhibitor of NaV1.5) blocked 60% of NaV1.5 currents in SK-OV-3 
cells whilst exemplifying a critical role in reducing SK-OV-3 cell migration and proliferation (Liu, 
et al., 2018). However, NaV1.5 is a major cardiac sodium channel, ultimately suggesting this 
would not make an ideal cancer target (Belau, et al., 2019). Nevertheless, the results exemplify 
the benefits of inhibiting certain VGSC and can be used as a framework for other investigations 
into the use of said toxins and the aforementioned sodium channels overexpressed in OC.  
Again, specific studies involving the aforementioned P.tra toxins and their inhibitory efforts in 
tumours have not been published to date. Using the research outlined here however, sets a 
framework in understanding how the potential blockades of VGSC can result in the reduced cell 
viability of SK-OV-3 cells. By extension, utilising isolated toxins from the P.tra venom could 
potentially have the same effect of inhibiting cell viability, which would suggest VGSC inhibitors 
present in the crude scorpion venom could have produced the inhibitory effects of the P.tra 
species witnessed in the DR assay in this investigation.  
H.mad and H.mye venom, unlike P.tra, did not exhibit inhibitory traits regardless of increasing 
the concentration to 500µg/ml; no more than 1% and 2.5% of inhibition was achieved in 
accordance to the venoms used at the specified dose. This ultimately suggested that H.mad and 
H.mye venoms were redundant in terms of the SK-OV-3 cell line as the 50% threshold was not 
achieved. To date, there are no published papers identifying specific components in the venom 
of H.mad or H.mye which by extension demonstrates there is no research published with an 
association between the antecedent venoms and their anticancer potential (PubMed, 2019). 
This would somewhat support the results illustrated here considering the venom did not inhibit 
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cell metabolism to a significant extent. Although this is the case for the specific species named, 
other species in the Heterometrus genus present more promise. 
Gupta et al 2007, identified the anticancer properties in venom from Heterometrus bengalensis 
(H.ben). Using an MTT assay, it was recognised that H.ben venom significantly inhibited cell 
growth in U937 and KF62 cells (human leukemic cell lines) achieving an LD50 of 41.5µg/ml and 
88.3µg/ml correspondingly. Furthermore, confocal microscopy identified chromatin 
condensation, margination and prominent nuclear disintegration in the dosed cells relative to 
untreated cells, whilst fluorescence microscopy illustrated the presence of apoptotic cells (early 
and late) in both cell lines when treated with venom. Finally, DNA fragmentation was 
significantly increased in the cell lines when dosed using a comet assay (p-value<0.05) (Gupta, 
et al., 2007).  
Subsequent to such findings, the same researchers investigated the H.ben venom further. Using 
HPLC, the specific protein responsible for the antiproliferative and apoptogenic effects was 
isolated and purified; this was established as Bengalin. Using the same cell lines mentioned 
above, an LD50 of metabolic inhibition was achieved at 3.7µg/ml and 4.1µg/ml respectively. 
Furthermore, inhibition of cell line proliferation transpired by apoptosis; this was evidenced by 
identifying extensive damage to nuclei, increase in early apoptotic cells and cell cycle arrest at 
the sub G1 phase. Furthermore, the Bax:Bcl2 (apoptosis regulator) ratio was elevated in the 
dosed cell lines. This was all achieved through fluorescence microscopy observations, flow 
cytometric analysis and Western Blot examination (Gupta, et al., 2010).  
Heterometrus laoticus (H.lao) is another species from the Heterometrus genus with medical 
utility. The venom from this species contains a peptide known as heteroscorpine-1 (HS-1) which 
possess a putative K+ channel blocking module (Uawonggul, et al., 2007). As previously specified, 
K+ channel inhibition is a potential mechanism specific in OC which can induce apoptosis (Comes, 
et al., 2015); thus, testing this specific compound against the SK-OV-3 cell line could present 
inhibitory effects.  
It is evident that there are medically useful species amongst the Heterometrus genus, however, 
this does not include H.mad and H.mye. This conforms to the results produced in the projects 
investigation. Both H.mad and H.mye did not significantly inhibit cell metabolism, in terms of 
the investigation at hand, this classifies the particular venoms as redundant. The fact that that 
literature concerning the medical benefits of the specified species is absent, especially 
concerning anticancer properties, illustrates either the lack of research into the venoms or the 
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lack of results produced from these species. Although the outcome of the assay does not 
transpire to a positive hit and thus a redundant route for a targeted-therapy, the results help to 
eliminate this venom in the quest for potential precision medicines in OC. Furthermore, the 
literature above solidifies that there are not only differences in venom components between 
scorpion families, but the venom constituents are also species specific. This validates that 
different species will elicit different effects on a molecular level which ultimately reinforces the 
importance of this project in establishing a panel of positive hit, and redundant venoms. 
Moreover, considering there are around 2,000 known scorpion species to date (National 
Geographic, 2019), the literature available as well as this project at hand only uses a small 
percentage of the known species which highlights how much potential this research still has to 
offer. Continued investigations in this field will aid in optimising the best scorpion-cancer 
combination, building an initial framework for novel therapeutics.  
Subsequent to the analysis of crude venoms, a number of fractioned venoms from a variety of 
species were investigated; this was done to establish exclusive fractions with cytotoxic 
propensities. Again, a 50% threshold was set and those fractions achieving 50% inhibition or 
more were carried forward for statistical analysis using a t-test. The results from the t-test 
indicated that fractions N.nig_r11, P.cav_r28 and P.cav_r30 were of significance in reducing SK-
OV-3 cell metabolism. Unfortunately, there were no stocks left of the P.cav_r30 fraction and 
therefore could not be analysed further. N.nig_r11 and P.cav_r28 were however carried forward 
for additional exploration.  
The N.nig_r11 fraction was utilised first. The results indicated that the fraction inhibited 50% of 
cell metabolism at a concentration of 37.23Pg/ml. Literature is relatively abundant in illustrating 
the cytotoxic ability of snake venoms and their potential in cancer (PubMed, 2019). Research 
has identified various crude snake venoms as well as isolated enzymes which obtain antitumor 
activities; these include metalloproteases, disintegrins, L-amino acid oxidases (LAAO), C-type 
lectins and phospholipases A2 (PLA2) (Calvete, et al., 2007). Mode of action includes apoptosis 
induction (PLA2, metalloproteases and LAAO), antiangiogenesis (disintegrins and lectins) as well 
as direct toxic action (PLA2) (Calderon, et al., 2014). It therefore came as no surprise that the 
snake venom used in this investigation significantly inhibited cell metabolism of SK-OV-3 cells. 
Although research is abundant in snake venom as whole and anticancer potential, N.nig venom 
explicitly has also gained some attention regarding its cytotoxic abilities in various cancers. For 
example, cytotoxin P4 was isolated from crude N.nig venom and contained 55% of the crude 
cytotoxic activity with a molecular weight of 8KD (Chaim-Matyas, et al., 1991). Borkow et al 
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1992, utilising the cytotoxin P4 identified that cell lysis occurred in leukaemia cells, B16F10 and 
WEHI-3B, at concentrations of 0.8µg/ml and 1µg/ml respectively (Borkow, et al., 1992). 
Suggestions for how inhibition of growth was caused included irreversible alterations on the 
cells completely destroying them, alterations to cell aggregation and finally loss of cell process 
viability (Calderon, et al., 2014). Furthermore, Chwetzoff et al 1989, identified a novel PLA2 
exclusive to N.nig that produced cytotoxic effects in epithelial FL cells. Fractioning the venom 
using HPLC, a specific PLA2 was identified and named nigexine; this is a single chain of 118 amino 
acids. Measuring the confluency of cell growth over a 15 day period, it was determined that 
nigexine at a concentration of 10-7M reduced cell proliferation by 70%. Moreover, cell viability 
of FL cells was reduced by 50% after 1 hour using a nigexine concentration of 2µM (Chwetzoff, 
et al., 1989).  
As a whole, the genus of Naja has shown huge potential in the field of oncology. Jokhio and 
Ansari 2005, validated the antimetastatic potential of Naja naja atra venom through decreasing 
the expression and activity of matrix metalloproteinase MMP-9. This was achieved through 
inactivating MAPK and PI3K/AKT signalling pathways which ultimately inhibited cell migration 
and invasion of cells initiating breast cancer (Jokhio & Ansari, 2005). In addition to this, Ebrahim 
et al 2016, using morphological analysis of HepG2 (hepatocellular carcinoma), MCF7 (breast 
cancer) and DU145 (prostate carcinoma) human cell lines, identified apoptosis occurred through 
cytoplasmic blebbing and chromatin condensation when using Naja naja oxiana venom. 
Furthermore, cell viability was inhibited by 50% at a concentration of 26.59µg/ml, 28.85µg/ml 
and 21.17µg/ml respectively (Ebrahim, et al., 2016).  
With regards to N.nig and the SK-OV-3 cell line, research is lacking. The potential presence of 
either cytotoxin P4 or nigexine in the N.nig_r11 fraction could have elucidated the inhibitory 
effects this fraction had in relation to the SK-OV-3 cell line. Ultimately, as this fraction within the 
project is considered as a positive hit, deeper understanding of the specific constituents within 
the cocktail is needed to aid in not only suggesting the potential proteins responsible for the 
cytotoxic effects, but also propose particular mechanisms in which the venom interacts with to 
cause the reduction is cell metabolism. This is why the current project identifying particular 
venoms with beneficial properties in reducing cell viability builds the framework in developing 
future explorations.  
The final DR utilised the P.cav_r28 fraction. Stocks of this venom were extremely limited 
therefore the maximum dose used in the assay was 15.63µg/ml which inhibited cell metabolism 
by 2.54%. This resulted in the characterisation of the venom being redundant as the 50% 
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threshold was not achieved. However, as demonstrated in the fraction dosing assay, this 
particular fraction achieved the 50% threshold at a concentration of 30µg/ml and therefore 
demonstrates inhibitory inclinations. The results of the DR, to an extent, do support this notion; 
a correlation between increasing venom concentration and increase in percent of inhibition 
begins at 3.91µg/ml. Percent of inhibition is low, however the reduced concentration utilised 
accounts for this. This suggests the venom is less potent but still active. Ultimately the venom 
cannot solely be classified as redundant and further investigations into this venom using a more 
concentrated dose is required.  
Available research regarding P.tra venom is extremely limited, especially considering this 
particular species is considered as medically useful; however restricted, contemporary research 
has started to demonstrate the anticancer and antimicrobial properties of scorpion venoms 
arousing interest (Estrada-Gomez, et al., 2017). Diego-Garcia et al 2012, fractioned crude P.cav 
venom using HPLC and identified a number of fractions that significantly inhibited VGPC activity 
using electrophysiological analysis. Results identified that fractions 49, 50 and 54 inhibited ion 
currents through the KV1.3 channel at 50µg of protein, whilst various other fractions blocked 
KV1.1 and KV1.2 channels also (Diego-Garcia, et al., 2012). Unfortunately, the molecular identity 
of the components in the fractions could not be determined. As mentioned previously, VGPC 
play an influencing role in tumorogenesis affecting cell proliferation, the cell cycle and 
differentiation elements associated with hallmarks of cancer. VGPC have been identified in 
various tumours, most appropriately, the KV1.3 channel has been identified in OC cell lines 
A2780 and SK-OV-3. Zhanping et al 2007, using MTT and flow cytometry identified the presence 
of the KV1.3 channel in A2780 cells which when blocked with 4-Aminopyridine (4-AP) inhibited 
cell proliferation. Furthermore, there was a significant increase in the percentage of cells present 
in the G0/G1 phase (p-value<0.05) whilst the percentage of cells in the S and G2/M phase 
significantly decreased (P-value<0.05), this suggests less cells are in the replication phase of the 
cell cycle explaining reduced cell growth (Zhanping, et al., 2007). Asher et al 2010, supported 
Zhanping’s findings; using the KV1.3 inhibitor 4-AP, cell proliferation of SK-OV-3 cells was 
significantly inhibited (p-value<0.001) (Asher, et al., 2010).  
Both researchers demonstrate the importance of the KV1.3 channel in the progression of OC 
whilst Diego-Garcia explicitly identifies particular P.cav fractions which significantly inhibited the 
channel. In regards to the results of the DR in this investigation, the concentration was too low 
to elicit a significant effect on cell metabolism, however when utilised at double the 
concentration, an LD50 is achieved. As the molecular components in the scorpion venom which 
stimulated the inhibition of VGPC were not identified, it cannot be explicitly said what proteins 
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were in the P.cav_r28 fraction, however it can be theorised that the fraction potentially 
contained a VGPC inhibitor similar to that investigated by Diego-Garcia. With the lack of research 
invested into the P.cav species, it is hard to determine the molecular mechanisms targeted by 
the species and therefore cannot unequivocally hypothesise the protein profile of the venom in 
this investigation without further analysis.  
With this in mind, it is important to consider further analyses; this includes what else could have 
been achieved in this project alone as well as future analyses which have the potential to build 
on from the foundations set within this investigation.  
First and foremost, re-running of DRs using increased concentrations of specific venoms would 
be beneficial in distinctly categorising the venoms into positive hits or redundant. As mentioned, 
the P.tra venom did evoke inhibition of the SK-OV-3 cell line, however, due to the arbitrary 50% 
threshold set throughout the project, at 200µg/ml, the venom could only generate a maximum 
inhibition of 44.55%. Although this did not reach the threshold, simply increasing the 
concentration to 1mg/ml and following the 1:2 dilution could prompt the venom in reaching the 
50% threshold and thus contribute to a positive hit provoking further investigation. The 
P.cav_r28 fraction would also benefit from this. As the stocks of this venom were low and there 
was not enough time to fraction more crude venom, 15.63µg/ml was the most concentrated 
dose utilised which did not reach the 50% threshold and was considered as redundant. However, 
when cells were dosed with this fraction at 30µg/ml, 50% inhibition of SK-OV-3 cell metabolism 
was exceeded. An additional DR using a higher concentration would once again solidify whether 
this venom warrants further investigation. Moreover, the project would benefit from 
investigating the inhibitory potential of the P.cav_r30 fraction also. Determining the LD50 of this 
fraction and comparing this to the P.cav_r28 fraction would assist in identifying if there are 
certain proteins specific to each fraction which, although both reduce cell viability, target 
separate mechanisms in the cancer.  
Further analysis could also involve reducing the arbitrary 50% threshold to 40% or 30% during 
the venom fraction dosing assay to identify more potentially significant fractions; nevertheless, 
it is important to consider that these fractions would be less potent. As illustrated in Table A.3 
of the appendix, fractions highlighted in purple achieved the 40% threshold, whilst fractions 
highlighted in blue reached the 30% threshold. When carrying such fractions forward for 
statistical analysis using a t-test, results determined that fraction A.cpi_r31 is significant at 40% 
(p-value=0.027) in reducing SK-OV-3 cell metabolism represented in Table A.4, whilst fractions 
N.nig_r16, A.cpi_r1 and A.cpi_r21 are significant at 30% (p-value=0.011, 0.040 and 0.018 
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respectively) in reducing cell metabolism demonstrated in Table A.5. This would offer additional 
species and fractions to investigate broadening the research capabilities.  
Alternative methods of analysis could also be utilised to enhance the investigation. Fractioning 
the venom of positive hits further would separate the venom into their individual protein 
constituents which could be additionally analysed for significance against the SK-OV-3 cell line. 
Those of significance could then be analysed using MS which would aid in the identification of 
the specific proteins responsible for the prevention of SK-OV-3 cell metabolism. This is a vital 
step when thinking about the drug discovery aspects of the project. Identifying the protein 
sequence and structure would not only help in understanding the interaction between the 
protein and molecular mechanisms within the cell line, but will also allow for the structure to be 
synthesised into a drug.  
Furthermore, Human Phospho-Kinase Antibody Arrays (Kinome Blots) could be used to identify 
exactly how the venoms, once fractioned, affect the phosphorylation profile of kinases and their 
protein substrates before and after dosing with the venom. This will identify if activity of certain 
receptors are being inhibited or knocked down ultimately affecting downstream signalling of 
said receptors that promote proliferation for instance and therefore reducing cell metabolism. 
An investigation such as this would also assist in identifying a certain molecular mechanism in 
the cell line which could be a target in other cancer types. For example, if the venom reduced 
the expression of EGFR in the SK-OV-3 cell line, it is known that non-small cell lung cancer also 
overexpresses this receptor and therefore could potentially procure the benefits of the specific 
venom used (Jurisic, et al., 2018). Moreover, using additional cell lines of the same and 
alternative cancer types would further enhance the understanding in determining if the benefits 
of the venom are cell line and/or cell type specific. Again, this would contribute to the 
development of a panel of venoms with anticancer properties regarding certain cancer cell lines. 
In addition to researching the anticancer benefits of certain venom components, it would also 
be advantageous to investigate the effects of such components in regards to normal, healthy 
cells. This would not only identify the selectivity of the venom for cancer-cells, but could also 
describe the interaction with normal cells demonstrating potential side effects, another 
important aspect of drug discovery.  
To date, contemporary research is lacking in the investigations into specific anticancer 
properties of certain venoms in relation to specific cancer types. In this investigation, the results 
revealed that several animal venoms contain anticancer properties concerning the SK-OV-3 cell 
line through inhibiting cell metabolism. Although this is only a first step of many into the 
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therapeutics community, the aforementioned analyses have allowed the framework to be 
constructed. Identifying the specific venoms which positively hit the cell line as well as those 
that do not, underpins the basic knowledge for further investigations. With this in mind, the 
foundations set here moves the identification and production of novel therapies regarding OC 
in the right direction.  
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APPENDIX 
Table A.1. The calculated Z-Factors for the optimal SK-OV-3 cell number of 1x105. From the results in this 
table, it is clear that at all time points the Z-Factor is above 0.5 thus categorising this cell number as robust.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Z Factor 
Time  Z Factor  
0 0.522 
15 0.664 
30 0.770 
45 0.807 
60 0.837 
90 0.899 
120 0.942 
150 0.961 
180 0.968 
210 0.967 
240 0.964 
270 0.964 
300 0.958 
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Figure A.1. The processed data of the Z’ assay for the LDϵ0 of N.nig crude venom. This was the first Z’ 
assay attempt. The Z-factor is calculated every 15 min. for 1 hour and then every 30 min for the following 
4 hours. A Z-factor above 0.5 is not achieved throughout the duration of the assay.  
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Figure A.2. The raw data collected from the FLUOstar Omega Microplate Reader at time point 300 min 
for the first Z’ assay. The positive controls are highlighted by green boxes to illustrate the areas of variation 
in the data. The calculated mean for the positive control was 46837.16 and 89323.63 for the negative 
control.  
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Figure A.3. The processed data of the Z’ assay for the LDϵ0 of N.nig crude venom. This was the second Z’ 
assay attempt. The Z-factor is calculated every 15 min. for 1 hour and then every 30 min for the following 
4 hours. A Z-factor above 0.5 is only achieved between 30 and 90 min. before returning below 0.5 and 
classified as a poor assay.  
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Figure A.4. The raw data collected from the FLUOstar Omega Microplate Reader at time point 300 min 
for the second Z’ assay. The positive control highlighted by the green box illustrates the areas of variation 
in the data. The calculated mean for the positive control was 54399.94 and 124608.30 for the negative 
control. 
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Figure A.5. The processed data of the Z’ assay for the LDϵ0 of N.nig crude venom. This was the third Z’ 
assay attempt. The Z-factor is calculated every 15 min. for 1 hour and then every 30 min for the following 
4 hours. A Z-factor above 0 is not achieved throughout the duration of the assay thus classified as a poor 
assay.  
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Figure A.6. The raw data collected from the FLUOstar Omega Microplate Reader at time point 300 min 
for the second Z’ assay. The green boxes highlight the wells amongst the negative control which produced 
variation. The calculated mean for the positive control was 6017.146 and 101305.40 for the negative 
control. 
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Table A.2. The calculated LD90 of crude N.nig venom using GraphPad. The ‘ECF’ calculates the LDϵ0 to be 
24.13µg/ml.  
log(agonist) vs. response -- Find ECanything 
  
Best-fit values   
LOGECF 1.383 
HILLSLOPE 6.082 
F = 90.00 
BOTTOM 3.845 
TOP 100.6 
ECF 24.13 
Span 96.73 
Std. Error   
LOGECF 0.04160 
HILLSLOPE 1.307 
BOTTOM 0.9000 
TOP 0.9767 
Span 1.374 
95% Confidence Intervals   
LOGECF 1.284 to 1.481 
HILLSLOPE 2.991 to 9.174 
BOTTOM 1.717 to 5.974 
TOP 98.26 to 102.9 
ECF 19.24 to 30.27 
Span 93.48 to 99.98 
Goodness of Fit   
Degrees of Freedom 7 
R² 0.9988 
Absolute Sum of Squares 26.97 
Sy.x 1.963 
Constraints   
F F = 90.00 
Number of points   
Analyzed 11 
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Table A.3. The average fluorescence, percentage growth and inhibition as well as standard deviation of 
the venom fraction dosing assay. Inhibition highlighted as GREEN indicates those fractions which inhibited 
50% or more of cell metabolism; highlighted as PURPLE indicates those fractions which inhibited 40% or 
more of cell metabolism; highlighted as BLUE indicates those fractions which inhibited 30% or more of 
cell metabolism.  
Fraction Fluorescence %Growth  %Inhibition StDev StDev (%) 
 N.nig r1 34616.00000 32.34176 67.65824 52046.62947 51.00019 
 N.nig r2 44775.33333 42.64393 57.35607 48929.51461 47.94575 
 N.nig r3 77685.00000 75.84900 24.15100 18927.25212 18.54670 
 N.nig r4 89920.00000 87.76125 12.23875 14437.86234 14.14758 
 N.nig r5 64299.33333 62.70748 37.29252 46063.01391 45.13688 
 N.nig r6 60942.66667 59.19863 40.80137 53735.77425 52.65537 
 N.nig r7 91966.66667 90.06309 9.93691 8841.16697 8.66341 
 N.nig r8 39470.33333 38.25868 61.74132 34468.91432 33.77589 
 N.nig r9 63840.00000 62.18271 37.81729 26461.19342 25.92917 
 N.nig r10 43665.33333 43.10749 56.89251 27336.87272 26.78724 
 N.nig r11 36174.66667 35.21483 64.78517 8163.32587 7.99920 
 N.nig r12 88009.00000 86.33496 13.66504 23269.23684 22.80139 
 N.nig r13 95491.33333 93.87706 6.12294 29957.85514 29.35553 
 N.nig r14 83067.66667 81.74866 18.25134 39606.19765 38.80988 
 N.nig r15 104728.33333 102.52786 -2.52786 8703.69441 8.52870 
 N.nig r16 68954.00000 67.68197 32.31803 6066.02770 5.94407 
 N.nig r17 96989.00000 95.00551 4.99449 16350.01365 16.02128 
 N.nig r18 96877.66667 94.86351 5.13649 5203.59880 5.09898 
 N.nig r19 99428.33333 97.49187 2.50813 8077.28076 7.91488 
 N.nig r20 101408.66667 99.40432 0.59568 6045.05587 5.92352 
 N.nig r21 91195.33333 89.42394 10.57606 24199.31537 23.71277 
 N.nig r22 87155.66667 85.43063 14.56937 28209.31793 27.64215 
 N.nig r23 99662.66667 97.74905 2.25095 3058.23683 2.99675 
A.cpi r1 61295.00000 60.56825 39.43175 2585.18239 2.53321 
A.cpi r2 96362.00000 94.36326 5.63674 7993.54008 7.83282 
A.cpi r4 99147.66667 97.12330 2.87670 7148.88777 7.00515 
A.cpi r7 102329.33333 100.30616 -0.30616 5583.70248 5.47144 
A.cpi r9 94513.66667 92.67673 7.32327 10946.10512 10.72602 
A.cpi r10 91316.66667 89.55436 10.44564 15295.62494 14.98809 
A.cpi r11 91135.33333 89.40564 10.59436 16917.50260 16.57736 
A.cpi r12 99935.00000 97.98535 2.01465 4754.07152 4.65849 
A.cpi r13 62276.33333 62.11057 37.88943 26338.34194 25.80879 
A.cpi r14 89287.33333 86.96153 13.03847 19165.60650 18.78027 
A.cpi r15 87100.00000 85.43011 14.56989 23800.24176 23.32172 
A.cpi r16 103529.00000 101.67498 -1.67498 16547.07294 16.21438 
A.cpi r17 98365.66667 96.65395 3.34605 26426.20929 25.89489 
A.cpi r18 97469.00000 95.76458 4.23542 27292.86176 26.74412 
A.cpi r19 74210.66667 72.96367 27.03633 60579.42697 59.36143 
A.cpi r20 99476.00000 98.07765 1.92235 11108.30559 10.88496 
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A.cpi r21 69080.66667 67.99848 32.00152 3822.35089 3.74550 
A.cpi r22 88280.33333 86.18482 13.81518 16376.34496 16.04709 
A.cpi r23 101938.00000 99.98335 0.01665 8954.09309 8.77406 
A.cpi r24 104841.00000 102.78626 -2.78626 7245.01739 7.09935 
A.cpi r26 95192.00000 93.38158 6.61842 18641.79345 18.26699 
A.cpi r27 94555.66667 92.76255 7.23745 13705.78864 13.43022 
A.cpi r28 70786.33333 69.61719 30.38281 57068.11982 55.92072 
A.cpi r29 89896.33333 87.86374 12.13626 15716.98414 15.40098 
A.cpi r31 59309.33333 58.13172 41.86828 13009.17923 12.74762 
P.reg r1 93276.00000 91.32206 8.67794 11173.19198 10.94855 
P.reg r4 96380.33333 94.41480 5.58520 9001.74257 8.82076 
P.reg r5 99156.33333 97.16701 2.83299 5985.76080 5.86541 
P.reg r6 92063.00000 90.35253 9.64747 19234.59698 18.84787 
P.reg r11 99075.33333 97.14214 2.85786 5352.71196 5.24509 
P.reg r12  82077.66667 80.54068 19.45932 31136.11392 30.51010 
P.reg r13 81854.66667 80.40943 19.59057 4543.28189 4.45194 
P.reg r15 61177.00000 60.92769 39.07231 32596.41163 31.94103 
P.reg r16 58585.66667 55.61491 44.38509 48887.58978 47.90467 
P.reg r17 96049.00000 93.97528 6.02472 9425.03119 9.23553 
P.reg r18 97150.33333 95.13700 4.86300 7359.17640 7.21121 
P.reg r20 91135.33333 89.41088 10.58912 17928.22753 17.56777 
P.reg r21 84465.33333 82.97269 17.02731 23117.75366 22.65295 
P.reg r22 86232.66667 84.90659 15.09341 13501.12622 13.22968 
P.reg r23 89778.33333 88.17917 11.82083 1020.27072 0.99976 
P.reg r24 46081.33333 45.50254 54.49746 23592.17235 23.11783 
P.reg r25 63888.00000 60.75569 39.24431 51851.74068 50.80922 
P.reg r28 98680.00000 96.69541 3.30459 6110.40531 5.98755 
P.cav r1 95552.33333 93.66307 6.33693 8797.85521 8.62097 
P.cav r2 88005.33333 86.37004 13.62996 20843.60358 20.42453 
P.cav r3 81605.00000 80.16405 19.83595 23036.55094 22.57338 
P.cav r4  66358.66667 65.43794 34.56206 35786.73995 35.06722 
P.cav r5 81372.00000 80.21547 19.78453 7437.80068 7.28826 
P.cav r8 40595.66667 41.06678 58.93322 31856.79661 31.21629 
P.cav r9 57853.33333 54.95711 45.04289 47597.43784 46.64045 
P.cav r10 87186.66667 85.26222 14.73778 15133.54120 14.82927 
P.cav r11 91789.33333 90.00092 9.99908 17868.27973 17.50902 
P.cav r14 93038.66667 91.17927 8.82073 9898.96117 9.69993 
P.cav r15 81354.33333 80.04260 19.95740 23509.97108 23.03728 
P.cav r16 77051.66667 75.82216 24.17784 17396.38061 17.04661 
P.cav r17 93733.33333 92.21208 7.78792 5328.37126 5.22124 
P.cav r21 45649.66667 45.02276 54.97724 25535.44263 25.02203 
P.cav r22 68351.33333 66.11769 33.88231 30992.36681 30.36924 
P.cav r24 97427.00000 95.14690 4.85310 14398.09251 14.10861 
P.cav r25 80242.66667 78.32828 21.67172 24820.97380 24.32193 
P.cav r26 80940.66667 79.13961 20.86039 19870.67207 19.47116 
P.cav r27 57966.33333 57.03571 42.96429 46387.10629 45.45446 
P.cav r28 46282.00000 45.03549 54.96451 18711.78444 18.33557 
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P.cav r29 82177.00000 80.92288 19.07712 13000.73602 12.73935 
P.cav r30 30847.33333 31.02522 68.97478 22926.40474 22.46545 
P.cav r31 50135.33333 48.33664 51.66336 48062.43029 47.09610 
P.cav r32 92693.00000 90.42339 9.57661 15803.12662 15.48539 
P.cav r33 86762.33333 84.84149 15.15851 16571.83567 16.23865 
P.cav r34 86149.33333 84.71236 15.28764 6419.98702 6.29091 
26.92ug/ml 
N.nig 26567.66667 25.82356 74.17644 8088.19049 7.92557 
26.92ug/ml 
N.nig 25620.66667 25.07624 74.92376 3504.81959 3.43435 
PBS 101909.66667 99.88740 0.11260 5752.73364 5.63707 
PBS 102194.00000 100.11260 -0.11260 6958.65425 6.81874 
 
 
Table A.4. The statistical results of the t-test used to find what fractions significantly reduced cell 
metabolism of SK-OV-3 cells using a 40% pass threshold.  
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Table A.5. The statistical results of the t-test used to find what fractions significantly reduced cell 
metabolism of SK-OV-3 cells using a 30% pass threshold.  
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